Abacavir or its saltsPDL |
|
I |
DEC / 13 |
AbataceptPDL |
|
I |
DEC / 13 |
AbciximabPDL |
|
I |
DEC / 13 |
Abemaciclib or its saltsPDL |
|
I |
JUL / 19 |
Abiraterone or its derivativesPDL |
including but not limited to abiraterone acetate
|
I |
DEC / 13 |
Acalabrutinib or its saltsPDL |
|
I |
OCT / 19 |
Acamprosate or its saltsPDL |
|
I |
DEC / 13 |
Acarbose or its derivativesPDL |
|
I |
DEC / 13 |
Acebutolol or its saltsPDL |
|
I |
DEC / 13 |
Acepromazine or its saltsPDL |
for human use
|
I |
DEC / 13 |
AcetaminophenPDL |
when recommended for administration by intravenous injection
|
I |
DEC / 13 |
Acetaminophen and ibuprofen |
When sold in oral, fixed-dose combinations, in package sizes containing 20,000 mg or less of acetaminophen and 6,000 mg or less of ibuprofen*
*Note that this listing does not apply to products containing ibuprofen that would meet the criteria to be included on the Prescription Drug list, as these would require a prescription
|
III |
JUL / 20 |
Acetaminophen and ibuprofen |
When sold in oral, fixed-dose combinations, in package sizes containing either more than 20,000 mg of acetaminophen or more than 6,000 mg of ibuprofen*
*Note that this listing does not apply to products containing ibuprofen that would meet the criteria to be included on the Prescription Drug list, as these would require a prescription
|
II |
JUL / 20 |
Acetaminophen in sustained release formulations |
up to and including 650 mg per unit, in package sizes containing no more than 50 units
|
U |
JAN / 03 |
Acetaminophen in sustained release formulations. |
in strengths of greater than 650 mg per unit or in package sizes of more than 50 units
|
III |
JAN / 03 |
Acetaminophen. |
in immediate release tablets, capsules, suppositories or liquid |
U |
SEP / 99 |
AcetanilidePDL |
for human use
|
I |
DEC / 13 |
Acetarsol |
|
II |
SEP / 98 |
AcetazolamidePDL |
|
I |
DEC / 13 |
AcetohexamidePDL |
|
I |
DEC / 13 |
AcetylcarbromalPDL |
|
I |
DEC / 13 |
Acetylcholine ChloridePDL |
|
I |
DEC / 13 |
Acetylcysteine |
In injectable form
|
II |
SEP / 98 |
Acetylsalicylic acid and its salts |
oral preparations containing 80 mg or less per dosage unit and intended for pediatric use or rectal preparations containing 150 mg or less per dosage unit, in package sizes containing no more than 1.92 g of acetylsalicylic acid. |
II |
FEB / 02 |
Acetylsalicylic acid and its salts. |
in products for oral use in strengths of 325mg and 500mg per dosage unit |
U |
OCT / 00 |
Acetylsalicylic acid and its salts.. |
in products intended for oral adult use in strengths of 81 mg per dosage unit and 650 mg or greater per dosage unit, and in rectal preparations containing more than 150 mg per dosage unit |
III |
OCT / 00 |
Acitretin or its salts or derivativesPDL |
|
I |
DEC / 13 |
Aclidinium or its saltsPDL |
|
I |
DEC / 13 |
Aconiazide or its saltsPDL |
|
I |
DEC / 13 |
Acyclovir or its saltsPDL |
|
I |
DEC / 13 |
AdalimumabPDL |
|
I |
DEC / 13 |
Adapalene or its salts or derivativesPDL |
|
I |
DEC / 13 |
Adefovir or its salts or derivativesPDL |
including but not limited to adefovir dipivoxil
|
I |
DEC / 13 |
Adenosine or its saltsPDL |
when sold or recommended for administration by intravenous injection
|
I |
DEC / 13 |
Adiphene and its salts |
for parenteral use |
II |
SEP / 98 |
Adrenocortical hormones or their salts or derivativesPDL |
for human use including but not limited to: Betamethasone valerate, betamethasone sodium, betamethasone phosphate, betamethasone dipropionate, budesonide, ciclesonide, clobetasone, cortisone, dexamethasone sodium, dexamethasone phosphate, dexamethasone acetate, difluprednate, fludrocortisone acetate, flunisolide, fluticasone propionate, fluticasone furoate, hydrocortisone acetate, hydrocortisone aceponate, hydrocortisone sodium, methylprednisolone acetate, methylprednisolone, methylprednisolone succinate, methylprednisolone sodium, mometasone furoate, prednisolone acetate, prednisolone sodium, prednisolone phosphate, prednisone, triamcinolone acetonide, triamcinolone hexacetonide except: (a) hydrocortisone or hydrocortisone acetate, when sold as a single medicinal ingredient in a concentration that provides 1.0% or less hydrocortisone in preparations for topical use on the skin; or (b) hydrocortisone or hydrocortisone acetate, when sold in combination with any other nonprescription medicinal ingredient that provides 1.0% or less hydrocortisone in preparations for topical use on the skin; or (c) clobetasone butyrate when sold in a concentration of 0.05% in cream preparations for topical use on the skin; or (d) triamcinolone acetonide in a nasal spray that delivers 55 microgram (mcg)/spray for those 12 years of age and older; or, (e) mometasone furoate for the treatment of allergic rhinitis in a nasal spray that delivers 50 mcg/spray for those 12 years of age and older; or (f) fluticasone propionate for the treatment of allergic rhinitis in a nasal spray that delivers 50 microgram/spray for those 18 years of age and older.
|
I |
AUG / 16 |
Afatinib or its saltsPDL |
|
I |
DEC / 13 |
AfliberceptPDL |
|
I |
DEC / 13 |
AfoxolanerPDL |
|
I |
AUG / 14 |
Agalsidase AlfaPDL |
|
I |
APR / 07 |
Agalsidase BetaPDL |
|
I |
DEC / 14 |
AlbiglutidePDL |
|
I |
AUG / 15 |
AldesleukinPDL |
|
I |
DEC / 13 |
Alectinib or its saltsPDL |
|
I |
NOV / 16 |
AlefaceptPDL |
|
I |
DEC / 13 |
AlemtuzumabPDL |
|
I |
DEC / 13 |
Alendronic acid or its saltsPDL |
|
I |
DEC / 13 |
AlfacalcidolPDL |
|
I |
DEC / 13 |
Alfuzosin or its saltsPDL |
|
I |
DEC / 13 |
Alglucosidase alfaPDL |
|
I |
DEC / 13 |
AlirocumabPDL |
|
I |
AUG / 16 |
Aliskiren or its saltsPDL |
|
I |
DEC / 13 |
Alitretinoin or its salts or derivativesPDL |
|
I |
DEC / 13 |
Alkyl nitritesPDL |
|
I |
DEC / 13 |
Allergy serums and extracts |
|
I |
SEP / 99 |
Allethrins |
|
II |
SEP / 98 |
AllopurinolPDL |
|
I |
DEC / 13 |
AllylisopropylacetylureaPDL |
|
I |
DEC / 13 |
Almotriptan or its saltsPDL |
|
I |
DEC / 13 |
Alogliptin or its salts or its derivativesPDL |
|
I |
DEC / 13 |
Alpelisib or its saltsPDL |
|
I |
JUL / 20 |
Alpha-chloralosePDL |
|
I |
DEC / 13 |
Alpha-hydroxy acidsPDL |
including but not limited to citric acid, glycolic acid, lactic acid, malic acid, mandelic acid, ammonium glycolate, glycolic acid + ammonium glycolate, alpha-hydroxyethanoic acid + ammonium alpha-hydroxyethanoate, alpha-hydroxyoctanoic acid, alpha-hydroxycaprylic acid, hydroxycaprylic acid, mixed fruit acid, triple fruit acid, tri-alpha hydroxy fruit acids, alpha hydroxy and botanical complex, l-alpha hydroxy acid, glycomer in cross-linked fatty acids alpha nutrium, when sold in topical formulations containing alpha hydroxy acids alone or in combination at concentrations of greater than 30% and/or with a pH lower than 3.0, except when sold to be applied to warts, corns or calluses
|
I |
DEC / 14 |
Alpha1- proteinase inhibitor (human) |
|
I |
JAN / 06 |
Alphadolone or its saltsPDL |
|
I |
DEC / 13 |
AlphaxalonePDL |
including but not limited to alfaxalone, alphaxolone
|
I |
DEC / 13 |
Alteplase or its salts or derivativesPDL |
including but not limited to tenecteplase
|
I |
DEC / 13 |
AltrenogestPDL |
|
I |
DEC / 13 |
AltretaminePDL |
|
I |
DEC / 13 |
Alverine and its salts |
in injectable form
|
I |
SEP / 98 |
Amantadine or its saltsPDL |
|
I |
DEC / 13 |
Ambenonium ChloridePDL |
|
I |
DEC / 13 |
AmbrisentanPDL |
|
I |
DEC / 13 |
Amidones, their intermediates, salts, derivatives and salts of intermediates and derivativesN |
Including: Dimethylaminodiphenylbutanonitrile; Dipipanone; Isomethadone; Methadone; Normethadone; Norpipanone; Phenadoxone
|
I |
JUN / 02 |
Amifampridine or its salts or derivatives PDL |
|
I |
SEP / 20 |
Amifostine or its saltsPDL |
|
I |
DEC / 13 |
Amikacin or its salts or derivativesPDL |
PDL, including but not limited to amikacin sulfate
|
I |
DEC / 13 |
Amiloride or its saltsPDL |
|
I |
DEC / 13 |
Amineptine and any salt thereofC |
|
I |
NOV / 20 |
Amino Acid solutions |
in injectable form
|
I |
SEP / 99 |
4- Amino-pteroyl aspartic acid or its saltsPDL |
|
I |
DEC / 13 |
Aminocaproic acidPDL |
|
I |
DEC / 13 |
AminoglutethimidePDL |
|
I |
DEC / 13 |
Aminolevulinic acid or its salts or derivativesPDL |
|
I |
DEC / 13 |
AminophyllinePDL |
|
I |
DEC / 13 |
Aminopromazine [proquamezine] and its salts |
|
I |
SEP / 98 |
Aminopterin or its salts or derivativesPDL |
|
I |
DEC / 13 |
Aminopyrine or its derivativesPDL |
for human use
|
I |
DEC / 13 |
Aminorex, its salts, derivatives, isomers and analogues and salts of derivatives, isomers and analoguesC |
Including 4-Methylaminorex and 4,4'-Dimethylaminorex.
|
I |
DEC / 17 |
4- Aminosalicylic Acid or its saltsPDL |
|
I |
DEC / 13 |
5- Aminosalicylic acidPDL |
including but not limited to mesalazine
|
I |
DEC / 13 |
Amiodarone or its salts or derivativesPDL |
including but not limited to dronedarone
|
I |
DEC / 13 |
AmitrazPDL |
|
I |
DEC / 13 |
Amitriptyline or its saltsPDL |
|
I |
DEC / 13 |
AmivantamabPDL |
|
I |
JUN / 22 |
Amlexanox or its salts or derivativesPDL |
|
I |
DEC / 13 |
Amlodipine or its saltsPDL |
|
I |
DEC / 13 |
Ammonium bromidePDL |
|
I |
DEC / 13 |
AmoxapinePDL |
|
I |
DEC / 13 |
Amphetamines, their salts, derivatives, isomers and analogues and salts of derivatives, isomers and analoguesC |
Excluding those substances set out in item 1 of Part I of the schedule to Part J (of the Food and Drug Regulations) but including: amphetamine; methamphetamine; Benzphetamine
|
I |
JUN / 02 |
Amphotericin B or its salts or derivativesPDL |
|
I |
DEC / 13 |
Amprenavir or its salts or derivativesPDL |
including but not limited to fosamprenavir
|
I |
DEC / 13 |
Amprolium or its saltsPDL |
for human use
|
I |
DEC / 13 |
Ampromides, their salts, derivatives and salts of derivativesN |
Including: Diampromide, Phenampromide, Propiram
|
I |
JUN / 02 |
Amrinone or its saltsPDL |
|
I |
DEC / 13 |
Amsacrine or its saltsPDL |
|
I |
DEC / 13 |
Amylocaine and its salts |
for ophthalmic or parenteral use |
II |
SEP / 98 |
Amylocaine and its salts |
in preparations for topical use on mucous membranes except lozenges |
III |
SEP / 98 |
Anabolic steroids and their derivativesC |
Including: Androisoxazole; Androstanolone; Androstenediol; Bolandiol; Bolasterone; Bolazine; Boldenone; Bolenol; Calusterone; Clostebol; Drostanolone; Enestebol; Epitiostanol; Ethylestrenol; 4-Hydroxy-19-nor testosterone; Fluoxymesterone; Formebolone; Furazabol; Mebolazine; Mesabolone; Mesterolone; Metandienone; Metenolone; Methandriol; Methyltestosterone; Metribolone; Mibolerone; Nandrolone; Norboletone; Norclostebol; Norethandrolone; Oxabolone; Oxandrolone; Oxymesterone; Oxymetholone; Prasterone; Quinbolone; Stanozolol; Stenbolone; Testosterone; Tibolone; Tiomesterone; Trenbolone
|
I |
JUN / 02 |
Anagrelide or its saltsPDL |
|
I |
DEC / 13 |
Anakinra or its salts or derivativesPDL |
|
I |
DEC / 13 |
AnastrozolePDL |
|
I |
DEC / 13 |
AncestimPDL |
|
I |
DEC / 13 |
Anetholtrithione |
|
III |
SEP / 98 |
AnidulafunginPDL |
|
I |
DEC / 13 |
AnifrolumabPDL |
|
I |
JAN / 22 |
Anisotropine and its salts |
|
II |
SEP / 98 |
Antazoline and its salts |
|
III |
SEP / 98 |
Anthralin |
|
II |
SEP / 98 |
Anti-thymocyte globulinPDL |
|
I |
DEC / 13 |
Antihemophilic factor, human |
|
II |
SEP / 98 |
AntipyrinePDL |
for human use, except preparations for topical use
|
I |
DEC / 13 |
Antipyrine. |
except otic preparations
|
II |
SEP / 98 |
Antipyrine.. |
for otic use
|
III |
SEP / 98 |
Apalutamide or its saltsPDL |
|
I |
JUL / 18 |
Apixaban or its derivativesPDL |
|
I |
DEC / 13 |
Apomorphine or its saltsPDL |
|
I |
FEB / 17 |
Apraclonidine or its saltsPDL |
|
I |
DEC / 13 |
Apramycin or its saltsPDL |
|
I |
DEC / 18 |
ApremilastPDL |
|
I |
DEC / 14 |
Aprepitant or its derivativesPDL |
including but not limited to fosaprepitant
|
I |
DEC / 13 |
AprotininPDL |
|
I |
DEC / 13 |
Argatroban or its salts or derivativesPDL |
|
I |
DEC / 13 |
Aripiprazole or its saltsPDL |
|
I |
DEC / 13 |
Arsenic trioxidePDL |
|
I |
DEC / 13 |
Asenapine or its salts or derivativesPDL |
including but not limited to asenapine maleate
|
I |
DEC / 13 |
Asfotase alfaPDL |
|
I |
OCT / 15 |
AsparaginasePDL |
when sold for administration by injection
|
I |
DEC / 13 |
Astemizole or its saltsPDL |
|
I |
DEC / 13 |
AsunaprevirPDL |
|
I |
AUG / 16 |
Atazanavir or its saltsPDL |
|
I |
DEC / 13 |
Atenolol or its saltsPDL |
|
I |
DEC / 13 |
AtezolizumabPDL |
|
I |
MAY / 17 |
Atipamezole or its saltsPDL |
|
I |
DEC / 13 |
Atomoxetine or its saltsPDL |
|
I |
DEC / 13 |
Atorvastatin or its saltsPDL |
|
I |
DEC / 13 |
AtovaquonePDL |
|
I |
DEC / 13 |
Atracurium besilatePDL |
|
I |
DEC / 13 |
Atropine or its saltsPDL |
including but not limited to atropine sulphate, in ophthalmic or parenteral preparations
|
I |
DEC / 13 |
Avalglucosidase alfaPDL |
|
I |
JAN / 22 |
AvelumabPDL |
|
I |
MAR / 18 |
Avermectin or its derivativesPDL |
including but not limited to ivermectin, selamectin, doramectin for human use
|
I |
DEC / 13 |
Avermectin or its derivatives.PDL |
For veterinary use - including but not limited to Ivermectin, selamectin, doramectin. Ivermectin when when recommended for intramuscular injection for horses or for oral administration to dogs and cats, except doramectin.
|
I |
DEC / 13 |
Avilamycin or its salts or derivativesPDL |
|
I |
MAR / 14 |
Axicabtagene ciloleucelPDL |
|
I |
MAR / 19 |
Axitinib or its salts or derivativesPDL |
|
I |
DEC / 13 |
Azacitidine or its salts or derivativesPDL |
|
I |
DEC / 13 |
Azacyclonol or its saltsPDL |
|
I |
DEC / 13 |
AzaribinePDL |
|
I |
DEC / 13 |
Azathioprine or its saltsPDL |
|
I |
DEC / 13 |
Azatidine or its saltsPDL |
including but not limited to azatadine
|
I |
DEC / 13 |
Azelaic acidPDL |
|
I |
DEC / 13 |
Azelastine or its saltsPDL |
|
I |
DEC / 14 |
Azilsartan medoxomil or its salts or derivativesPDL |
|
I |
DEC / 13 |
Aztreonam or its saltsPDL |
|
I |
DEC / 13 |
Bacillus Calmette-Guérin (BCG)PDL |
Including but not limited to Bacillus Calmette-Guérin (BCG): Strain TICE, Strain Russian BCG-I, when sold or recommended as an antineoplastic agent.
|
I |
MAY / 21 |
Bacillus Calmette-Guérin (BCG) vaccine |
|
I |
FEB / 02 |
Bacitracin or its salts or derivativesPDL |
For veterinary use
|
I |
DEC / 18 |
Bacitracin or its salts or derivatives . |
For human use: for parenteral use
|
I |
SEP / 98 |
Bacitracin or its salts or derivatives .. |
For human use: for topical use
|
U |
SEP / 98 |
Bacitracin or its salts or derivatives … |
For human use: for ophthalmic use
|
III |
JUN / 06 |
Baclofen or its saltsPDL |
|
I |
DEC / 13 |
Baloxavir marboxilPDL |
|
I |
JUL / 20 |
Bambuterol or its saltsPDL |
|
I |
DEC / 13 |
BamlanivimabPDL |
|
I |
NOV / 20 |
Barbiturates, their salts and derivativesC |
Excluding the substances set out in items 6 and 7 of Part I of this schedule (Schedule G of the Food and Drug Regulations), as well as barbituric acid and its salts and 1,3-dimethylbarbituric acid and its salts, but including: Allobarbital; Alphenal; Amobarbital; Aprobarbital; Barbital; Butabarbital; Butalbital; Butallylonal; Butethal; Cyclobarbital; Cyclopal; Heptabarbital; Hexethal; Hexobarbital; Mephobarbital; Methabarbital; Methylphenobarbital; Propallylonal;
Phenobarbital; Probarbital; Phenylmethylbarbituric Acid; Sigmodal; Talbutal; Vinbarbital; Vinylbital
|
I |
JUN / 02 |
Baricitinib or its saltsPDL |
|
I |
OCT / 18 |
BasiliximabPDL |
|
I |
DEC / 13 |
Bazedoxifene or its saltsPDL |
|
I |
DEC / 14 |
BecaplerminPDL |
|
I |
DEC / 13 |
BedinvetmabPDL |
For veterinary use
|
I |
MAY / 21 |
BelimumabPDL |
|
I |
DEC / 13 |
Belumosudil or its saltsPDL |
|
I |
JUN / 22 |
BemegridePDL |
|
I |
DEC / 13 |
Benactyzine or its saltsPDL |
|
I |
DEC / 13 |
Benazepril or its salts or derivativesPDL |
including but not limited to benazepril hydrochloride
|
I |
DEC / 13 |
Bendamustine or its salts or derivativesPDL |
including but not limited to bendamustine hydrochloride
|
I |
DEC / 13 |
Bendazac or its saltsPDL |
|
I |
DEC / 13 |
Benoxaprofen or its saltsPDL |
|
I |
DEC / 13 |
Benoxinate hydrochloride |
oxybuprocaine for ophthalmic or parenteral use |
II |
SEP / 98 |
BenralizumabPDL |
|
I |
MAY / 18 |
Benserazide or its saltsPDL |
|
I |
DEC / 13 |
Bentiromide |
|
II |
SEP / 98 |
Benzalkonium and its salts |
liquid preparations in concentrations of more than 2% |
II |
SEP / 98 |
Benzazocines, their salts, derivatives and salts of derivativesN |
Including: Phenazocine, Metazocine, Pentazocine; but not including: Cyclazocine and its salts
|
I |
JUN / 02 |
Benzethonium chloride |
liquid preparations in concentrations of more than 1% |
II |
SEP / 98 |
Benzimidazoles, their salts, derivatives and salts of derivativesN |
Including: Clonitazene, Etonitazene
|
I |
JUN / 02 |
Benzocaine and its salts |
in injectable form
|
II |
SEP / 98 |
Benzodiazepines, their salts and derivativesTS |
Including: Alprazolam, Bromazepam, Brotizolam, Camazepam, Chlordiazepoxide, Clobazam, Clonazepam, Clorazepate, Cloxazolam, Delorazepam, Diazepam, Estazolam, Ethyl Loflazepate, Fludiazepam, Flurazepam, Halazepam, Haloxazolam, Ketazolam, Loprazolam, Lorazepam, Lormetazepam, Medazepam, Midazolam, Nimetazepam, Nitrazepam, Nordazepam, Oxazepam, Oxazolam, Pinazepam, Prazepam, Quazepam, Temazepam, Tetrazepam, Triazolam; but not including: Clozapine and any salt thereof, Flunitrazepam and any salts or derivatives thereof, Olanzapine and its salts, Clozapine N-oxide and its salts
|
I |
SEP / 98 |
Benzonatate |
|
III |
SEP / 98 |
Benzoyl peroxidePDL |
in concentrations greater than 5% or when sold in combination with another medicinal ingredient
|
I |
DEC / 13 |
Benzoyl peroxide. |
preparations of 5% or less as a single ingredient |
U |
MAY / 08 |
Benztropine or its saltsPDL |
including but not limited to benzatropine
|
I |
DEC / 13 |
Benzydamine or its saltsPDL |
|
I |
DEC / 13 |
Bepotastine or its salts or derivativesPDL |
|
I |
NOV / 16 |
BeractantPDL |
|
I |
DEC / 13 |
Besifloxacin or its saltsPDL |
|
I |
DEC / 13 |
Betahistine or its saltsPDL |
|
I |
DEC / 13 |
Betaine or its saltsPDL |
for human use, when sold or recommended for the treatment of homocystinuria
|
I |
DEC / 13 |
Betaine or its salts.PDL |
for veterinary use
|
I |
DEC / 13 |
Betaxolol or its saltsPDL |
|
I |
DEC / 13 |
Bethanechol chloridePDL |
|
I |
DEC / 13 |
Bethanidine or its saltsPDL |
|
I |
DEC / 13 |
BevacizumabPDL |
|
I |
DEC / 13 |
Bezafibrate or its salts or derivativesPDL |
|
I |
DEC / 13 |
BicalutamidePDL |
|
I |
DEC / 13 |
Bictegravir or its saltsPDL |
|
I |
AUG / 18 |
Bilastine or its salts or derivativesPDL |
|
I |
AUG / 16 |
BimekizumabPDL |
|
I |
JUN / 22 |
Binimetinib or its saltsPDL |
|
I |
MAY / 21 |
Biperiden or its saltsPDL |
|
I |
DEC / 13 |
Bisacodyl |
when sold in strengths of 5mg or less per oral dosage unit, in package sizes containing no more than 105 mg of bisacodyl
|
U |
JUL / 21 |
Bisacodyl |
when sold in strengths of 10mg or less per rectal dosage unit/suppository, in package sizes containing no more than 50mg of bisacodyl
|
U |
JUL / 21 |
Bisacodyl and its salts |
(except when sold in strengths of 5mg or less per oral dosage unit in package sizes containing no more than 105mg of bisacodyl and except when sold in strengths of 10mg or less per rectal dosage unit/suppository in package sizes containing no more than 50mg of bisacodyl)
|
III |
JUL / 21 |
Bishydroxycoumarin or its salts or derivativesPDL |
|
I |
DEC / 13 |
Bisoprolol or its saltsPDL |
|
I |
DEC / 13 |
Bitolterol or its saltsPDL |
|
I |
DEC / 13 |
BivalirudinPDL |
|
I |
DEC / 13 |
BleomycinPDL |
|
I |
DEC / 13 |
BlinatumomabPDL |
|
I |
AUG / 16 |
Boceprevir or its derivativesPDL |
|
I |
DEC / 13 |
BortezomibPDL |
|
I |
DEC / 13 |
Bosentan or its salts or derivativesPDL |
|
I |
DEC / 13 |
Bosutinib or its saltsPDL |
including but not limited to Bosutinib methanoate
|
I |
AUG / 14 |
Botulinum toxinPDL |
including but not limited to onabotulinumtoxin A, incobotulinumtoxin A, abobotulinumtoxin A, rimabotulinumtoxin B, prabotulinumtoxin A
|
I |
DEC / 13 |
Brentuximab vedotinPDL |
|
I |
DEC / 13 |
Bretylium tosylatePDL |
|
I |
DEC / 13 |
Brexpiprazole or its saltsPDL |
|
I |
APR / 17 |
Brexucabtagene autoleucelPDL |
|
I |
JUL / 21 |
Brigatinib or its saltsPDL |
|
I |
AUG / 18 |
Brilliant Blue G or its derivativesPDL |
|
I |
MAY / 21 |
Brimonidine or its saltsPDL |
Except when sold as brimonidine tartrate ophthalmic solution in concentrations up to and including 0.025%, used for the relief of redness of the eye due to minor eye irritations caused by environmental allergies, dryness and fatigue for adults of 18 years and older
|
I |
MAY / 22 |
Brimonidine tartrate |
Ophthalmic solution in concentrations up to and including 0.025%, used for the relief of redness of the eye due to minor eye irritations caused by environmental allergies, dryness and fatigue for adults of 18 years and older
|
III |
MAY / 22 |
Brivaracetam or its derivativesPDL |
|
I |
AUG / 16 |
BrodalumabPDL |
|
I |
MAY / 18 |
BrolucizumabPDL |
|
I |
JUL / 20 |
BromalPDL |
|
I |
DEC / 13 |
Bromal hydratePDL |
|
I |
DEC / 13 |
BrometonePDL |
|
I |
DEC / 13 |
Bromfenac or its saltsPDL |
|
I |
MAY / 15 |
BromisovalPDL |
|
I |
DEC / 13 |
Bromocriptine or its saltsPDL |
|
I |
DEC / 13 |
BromoformPDL |
|
I |
DEC / 13 |
Brompheniramine and its salts |
as a single entity for the treatment of allergies |
III |
JAN / 03 |
Brompheniramine and its salts. |
in combination products for the relief of cough and cold symptoms |
U |
JAN / 03 |
Buclizine |
|
II |
SEP / 98 |
Bufexamac |
|
II |
SEP / 98 |
Bumetanide or its salts or derivativesPDL |
|
I |
DEC / 13 |
Bupivacaine and its salts |
for parenteral or ophthalmic use |
II |
SEP / 98 |
Bupivacaine and its salts |
for topical use on mucous membranes except lozenges |
III |
SEP / 98 |
Bupropion or its saltsPDL |
|
I |
DEC / 13 |
BurosumabPDL |
|
I |
DEC / 18 |
Buserelin or its saltsPDL |
|
I |
DEC / 13 |
Buspirone or its saltsPDL |
|
I |
DEC / 13 |
BusulfanPDL |
|
I |
DEC / 13 |
Butacaine and its salts |
for ophthalmic or parenteral use |
II |
SEP / 98 |
Butaperazine or its saltsPDL |
|
I |
DEC / 13 |
Butenafine |
1% cream |
U |
SEP / 99 |
Butoconazole or its saltsPDL |
|
I |
DEC / 13 |
Butorphanol and its salts C |
|
I |
JUN / 02 |
Butyl chloral hydratePDL |
|
I |
DEC / 13 |
Cabergoline or its saltsPDL |
|
I |
DEC / 13 |
Cabotegravir or its saltsPDL |
|
I |
JUL / 20 |
Cabozantinib or its saltsPDL |
|
I |
NOV / 18 |
CalcifediolPDL |
|
I |
JUL / 18 |
CalcipotriolPDL |
|
I |
DEC / 13 |
CalcitoninPDL |
|
I |
DEC / 13 |
CalcitriolPDL |
|
I |
DEC / 13 |
Calcium bromidePDL |
|
I |
DEC / 13 |
Calcium bromolactobionatePDL |
|
I |
DEC / 13 |
Calcium carbimidePDL |
|
I |
DEC / 13 |
Calcium chloride in injectable form for parenteral nutrition |
|
I |
JAN / 03 |
Calcium disodium edetate |
|
II |
SEP / 98 |
Calcium gluconate in injectable form for parenteral nutrition |
|
I |
JAN / 03 |
Calcium polycarbophil |
|
III |
SEP / 98 |
Calcium salts when sold for the treatment of hyperphosphatemiaPDL |
|
I |
DEC / 13 |
CanagliflozinPDL |
|
I |
JUL / 14 |
CanakinumabPDL |
|
I |
DEC / 13 |
Candesartan or its salts or derivativesPDL |
including but not limited to candesartan cilexetil
|
I |
DEC / 13 |
Candicidin or its salts or derivativesPDL |
|
I |
DEC / 13 |
CaplacizumabPDL |
|
I |
JUL / 20 |
Capreomycin or its salts or derivativesPDL |
|
I |
DEC / 13 |
Captodiamine or its saltsPDL |
|
I |
DEC / 13 |
Captopril or its saltsPDL |
|
I |
DEC / 13 |
CarbacholPDL |
|
I |
DEC / 13 |
CarbamazepinePDL |
|
I |
DEC / 13 |
Carbapenem salts or derivativesPDL |
Including but not limited to: Doripenem, ertapenem, imipenem, meropenem
|
I |
DEC / 18 |
Carbenoxolone or its saltsPDL |
|
I |
DEC / 13 |
Carbetocin or its saltsPDL |
|
I |
DEC / 13 |
Carbidopa or its saltsPDL |
|
I |
DEC / 13 |
CarbimazolePDL |
|
I |
DEC / 13 |
Carbinoxamine or its salts |
|
III |
SEP / 98 |
CarbocisteinePDL |
|
I |
DEC / 13 |
Carbomycin or its salts or derivativesPDL |
|
I |
DEC / 13 |
CarboplatinPDL |
|
I |
DEC / 13 |
CarbromalPDL |
|
I |
DEC / 13 |
CarfilzomibPDL |
|
I |
AUG / 16 |
Carglumic acid or its salts or derivativesPDL |
|
I |
JUN / 15 |
Cariprazine or its saltsPDL |
|
I |
JUN / 22 |
CarisoprodolPDL |
|
I |
DEC / 13 |
CarmustinePDL |
|
I |
DEC / 13 |
Carphenazine or its saltsPDL |
|
I |
DEC / 13 |
Carprofen or its salts or derivativesPDL |
|
I |
DEC / 13 |
Carvedilol and its saltsPDL |
|
I |
DEC / 13 |
CasirivimabPDL |
|
I |
JUN / 21 |
Caspofungin or its salts or derivativesPDL |
|
I |
DEC / 13 |
CatumaxomabPDL |
|
I |
DEC / 13 |
Cedazuridine PDL |
When used in combination with another drug.
|
I |
SEP / 20 |
Celecoxib or its saltsPDL |
|
I |
DEC / 13 |
CemiplimabPDL |
|
I |
JUL / 19 |
CenegerminPDL |
|
I |
MAR / 19 |
Cephalosporin C or its salts or derivatives or analogsPDL |
Including but not limited to: Cephalexin (cefalexin), cephapirin (cefapirin), cefaclor, cefadroxil, cefazolin, cefonicide, cefoxitin, cefprozil, cefuroxime, loracarbef, cefdinir, cefixime, cefoperazone, cefotaxime, cefpodoxime proxetil, ceftazidime, ceftibuten, ceftriaxone, cefepime, ceftobiprole, ceftolozane, cefovecin, ceftiofur
|
I |
DEC / 18 |
Cerapon |
|
III |
SEP / 98 |
Ceritinib or its saltsPDL |
|
I |
MAY / 15 |
Cerivastatin or its saltsPDL |
|
I |
DEC / 13 |
Cerliponase alfaPDL |
|
I |
FEB / 19 |
Certolizumab pegolPDL |
|
I |
DEC / 13 |
Cetirizine or its saltsPDL |
see hydroxyzine or its salts or derivatives
|
I |
DEC / 13 |
Cetirizine or its salts. |
in concentrations of 10 mg equivalent to 8.5 mg or less of cetirizine base per dosage unit, in products marketed for pediatric use (under 12 years of age) |
III |
JUL / 02 |
Cetirizine or its salts.. |
in concentrations of 10mg equivalent to 8.5mg or less of cetirizine base per dosage unit) in products marketed for adult use (age 12 and over)
|
U |
JUL / 02 |
Cetrorelix or its saltsPDL |
|
I |
DEC / 13 |
CetuximabPDL |
|
I |
DEC / 13 |
Charcoal (activated) |
except for use in poisoning treatment |
U |
JUN / 98 |
Charcoal [activated] for use in poisoning treatment |
|
II |
SEP / 98 |
Chlophedianol and its salts |
Clofedanol.
|
III |
SEP / 98 |
ChloralPDL |
|
I |
DEC / 13 |
Chloral hydratePDL |
|
I |
DEC / 13 |
ChloralformamidePDL |
|
I |
DEC / 13 |
ChloralimidePDL |
|
I |
DEC / 13 |
Chlorambucil or its salts or derivativesPDL |
|
I |
DEC / 13 |
Chloramphenicol or its salts or derivativesPDL |
|
I |
DEC / 13 |
Chlorcyclizine or its saltsPDL |
except in preparations for external use
|
I |
DEC / 13 |
Chlorhexidine or its saltsPDL |
for human use when used as a topical oral preparation
|
I |
DEC / 13 |
Chlorisondamine or its saltsPDL |
|
I |
DEC / 13 |
ChlormezanonePDL |
|
I |
DEC / 13 |
Chloroprocaine and its salts |
for parenteral or ophthalmic use |
II |
SEP / 98 |
Chloroprocaine and its salts |
for topical use on mucous membranes, except lozenges |
III |
SEP / 98 |
Chloroquine or its saltsPDL |
|
I |
DEC / 13 |
Chlorothiazide or its salts or derivativesPDL |
for human use
|
I |
DEC / 13 |
Chlorpheniramine and its salts and preparations |
|
U |
AUG / 97 |
Chlorphentermine and any salt thereofC |
|
I |
JUN / 02 |
Chlorpromazine or its saltsPDL |
for human use
|
I |
DEC / 13 |
ChlorpropamidePDL |
|
I |
DEC / 13 |
Chlorprothixene or its saltsPDL |
|
I |
DEC / 13 |
Chlortetracycline or its saltsPDL |
For veterinary use
|
I |
DEC / 18 |
Chlorzoxazone and its salts |
|
III |
SEP / 98 |
Cholecystokinin |
|
II |
SEP / 98 |
Cholera vaccine |
except oral, inactivated, when used for prophylaxis against travellers' diarrhea & due to enterotoxigenic escherichia coli (ETEC) |
I |
JAN / 04 |
Cholera vaccine (oral, inactivated) |
when used for prophylaxis against travellers' diarrhea & due to enterotoxigenic escherichia coli (ETEC) |
II |
JAN / 04 |
Cholestyramine resinPDL |
for human use
|
I |
DEC / 13 |
Choline bitartrate |
in injectable form
|
II |
SEP / 98 |
Choline salicylatePDL |
when sold in combination with magnesium salicylate
|
I |
DEC / 13 |
Choline theophyllinatePDL |
|
I |
DEC / 13 |
Choriogonadotropin alfaPDL |
|
I |
DEC / 13 |
Chromium Chloride (chromic chloride) in injectable form for parenteral nutrition |
|
I |
JAN / 03 |
Chymopapain |
in injectable form
|
II |
SEP / 98 |
Chymotrypsin |
in injectable form
|
II |
SEP / 98 |
CiclesonidePDL |
For veterinary use
|
I |
JUL / 20 |
Ciclopirox or its saltsPDL |
|
I |
DEC / 13 |
Cidofovir or its salts or its derivativesPDL |
|
I |
MAY / 18 |
Cilastatin or its saltsPDL |
|
I |
DEC / 13 |
Cilazapril or its salts or derivativesPDL |
|
I |
DEC / 13 |
CilgavimabPDL |
|
I |
JUN / 22 |
Cimetidine or its saltsPDL |
for veterinary use
|
I |
DEC / 13 |
Cimetidine or its salts.PDL |
except when sold in concentrations of 200 milligrams or less per oral dosage unit and indicated for the treatment of heartburn
|
I |
DEC / 13 |
Cimetidine or its salts.. |
when sold in concentrations of 100 mg or less per dosage unit and indicated for the treatment of heartburn
|
III |
DEC / 13 |
Cinacalcet or its saltsPDL |
|
I |
DEC / 13 |
Cinchocaine (dibucaine) and its salts |
for ophthalmic or parenteral use |
II |
SEP / 98 |
Cinchophene or its saltsPDL |
|
I |
DEC / 13 |
Cinnamedrine |
|
U |
|
CinoxacinPDL |
|
I |
DEC / 13 |
Ciprofloxacin or its saltsPDL |
|
I |
DEC / 13 |
Cisapride or its saltsPDL |
|
I |
SEP / 98 |
Cisatracurium besilatePDL |
|
I |
DEC / 13 |
CisplatinPDL |
|
I |
DEC / 13 |
Citalopram or its saltsPDL |
|
I |
DEC / 13 |
Cladribine or its salts or derivativesPDL |
|
I |
DEC / 13 |
Clemastine and its salts |
|
III |
SEP / 98 |
Clenbuterol or its saltsPDL |
|
I |
DEC / 13 |
Clevidipine or its saltsPDL |
|
I |
DEC / 13 |
Clidinium and its salts |
|
II |
SEP / 98 |
Clobetasone butyrate |
when sold in a concentration of 0.05% clobetasone butyrate in cream preparations for topical use on the skin |
II |
OCT / 06 |
Clodronic acid or its saltsPDL |
|
I |
DEC / 13 |
ClofarabinePDL |
|
I |
DEC / 13 |
ClofibratePDL |
|
I |
DEC / 13 |
Clomiphene or its saltsPDL |
|
I |
DEC / 13 |
Clomipramine or its saltsPDL |
|
I |
DEC / 13 |
Clonidine or its saltsPDL |
|
I |
DEC / 13 |
Clopidogrel or its saltsPDL |
|
I |
DEC / 13 |
Clorazepic acid or its saltsPDL |
|
I |
DEC / 13 |
Closantel or its saltsPDL |
for veterinary use, including but not limited to closantel sodium
|
I |
AUG / 16 |
Clotiazepam and any salt thereofTS |
|
I |
JUN / 02 |
Clotrimazole and its salts.. |
for human use in preparations for topical use |
U |
DEC / 13 |
Clotrimazole or its saltsPDL |
for human use, except in preparations for topical or vaginal use
|
I |
DEC / 13 |
Clotrimazole or its salts. |
for human use in preparations for intra-vaginal use
|
III |
DEC / 13 |
Clozapine or its saltsPDL |
|
I |
DEC / 13 |
Coal tar |
in concentrations of more than 10% |
II |
SEP / 98 |
Coal tar. |
in concentrations up to and including 10% |
U |
|
Cobicistat or its saltsPDL |
|
I |
DEC / 18 |
Cobimetinib or its saltsPDL |
|
I |
AUG / 16 |
Coca (Erythroxylum), its preparations, derivatives, alkaloids and saltsN |
Including: Coca leaves; Cocaine; Ecgonine; but not including 123l-ioflupane
|
I |
JUN / 02 |
Codeine and its salts |
in preparations exempted from the Regulations to the Controlled Drugs and Substances Act |
II |
SEP / 98 |
ColchicinePDL |
|
I |
DEC / 13 |
Colesevelam or its saltsPDL |
including but not limited to colesevelam hydrochloride
|
I |
DEC / 13 |
Colestipol or its saltsPDL |
|
I |
DEC / 13 |
Colfosceril or its derivativesPDL |
|
I |
DEC / 13 |
Colistin or its salt or derivativesPDL |
including but not limited to colistimethate
|
I |
DEC / 13 |
CollagenasePDL |
when recommended for the debridement of severe burns and skin ulcers
|
I |
DEC / 13 |
Copper chloride (cupric chloride) in injectable form for parenteral nutrition |
|
I |
JAN / 03 |
Copper sulfate in injectable form for parenteral nutrition |
|
I |
JAN / 03 |
CrisaborolePDL |
|
I |
JUL / 18 |
Crizotinib or its salts or derivativesPDL |
|
I |
DEC / 13 |
Cromoglicic (cromoglycic) acid or its saltsPDL |
except sodium cromoglicate (cromoglycate) in solutions for ophthalmic or nasal use in concentrations of 2% or less [*see sodium cromoglicate (cromoglycate)]
|
I |
DEC / 13 |
Crotamiton |
|
II |
SEP / 98 |
Cyclandelate |
|
II |
SEP / 98 |
Cyclazocine and its salts |
|
II |
SEP / 98 |
CyclizinePDL |
for human use
|
I |
DEC / 13 |
Cyclobenzaprine or its saltsPDL |
|
I |
DEC / 13 |
Cyclomethacaine and its salts |
for ophthalmic or parenteral use |
II |
SEP / 98 |
Cyclopentamine and its salts |
|
II |
SEP / 98 |
Cyclopentolate or its salts |
except in products for ophthalmic or parenteral use |
II |
SEP / 98 |
Cyclopentolate or its saltsPDL |
in preparations for parenteral or ophthalmic use, except when sold for use in diagnostic procedures to an optometrist registered in a province of Canada
|
I |
DEC / 13 |
CyclophosphamidePDL |
|
I |
DEC / 13 |
CycloserinePDL |
|
I |
DEC / 13 |
CyclosporinePDL |
including but not limited to ciclosporin
|
I |
DEC / 13 |
Cyproheptadine and its salts |
|
II |
SEP / 98 |
Cyproterone acetatePDL |
including but not limited to cyproterone acetate
|
I |
DEC / 13 |
Cysteamine (Mercaptamine) or its saltsPDL |
|
I |
AUG / 17 |
Cytarabine or its saltsPDL |
|
I |
DEC / 13 |
Cytomegalovirus immune globulins |
|
I |
FEB / 02 |
Dabigatran or its salts or derivativesPDL |
including but not limited to dabigatran etexilate
|
I |
DEC / 13 |
Dabrafenib or its saltsPDL |
|
I |
DEC / 13 |
DacarbazinePDL |
|
I |
DEC / 13 |
Daclatasvir or its saltsPDL |
|
I |
OCT / 15 |
DaclizumabPDL |
|
I |
DEC / 13 |
Daclizumab betaPDL |
|
I |
FEB / 17 |
Dacomitinib or its saltsPDL |
|
I |
MAR / 19 |
DactinomycinPDL |
|
I |
DEC / 13 |
Dalbavancin or its saltsPDL |
|
I |
OCT / 18 |
Dalfopristin or its saltsPDL |
|
I |
DEC / 13 |
Dalteparin or its saltsPDL |
|
I |
DEC / 13 |
Danaparoid or its salts or derivativesPDL |
|
I |
DEC / 13 |
DanazolPDL |
|
I |
DEC / 13 |
Danofloxacin or its saltsPDL |
|
I |
DEC / 13 |
Danthron |
|
III |
SEP / 98 |
Dantrolene or its saltsPDL |
|
I |
DEC / 13 |
Dapagliflozin or its derivativesPDL |
|
I |
MAR / 15 |
Dapiprazole or its saltsPDL |
|
I |
DEC / 13 |
DaptomycinPDL |
|
I |
DEC / 13 |
DaratumumabPDL |
|
I |
AUG / 16 |
Darifenacin or its saltsPDL |
|
I |
DEC / 13 |
DarolutamidePDL |
|
I |
JUL / 20 |
DarunavirPDL |
|
I |
DEC / 13 |
Dasabuvir or its saltsPDL |
|
I |
MAR / 15 |
DasatanibPDL |
|
I |
DEC / 13 |
Daunorubicin or its saltsPDL |
|
I |
DEC / 13 |
Debrisoquin or its saltsPDL |
|
I |
DEC / 13 |
Decitabine or its saltsPDL |
|
I |
FEB / 19 |
DeferasiroxPDL |
|
I |
DEC / 13 |
Deferiprone or its derivativesPDL |
|
I |
MAR / 15 |
Deferoxamine or its saltsPDL |
|
I |
DEC / 13 |
Defibrotide or its salts or derivativesPDL |
|
I |
SEP / 17 |
Degarelix or its salts or derivativesPDL |
|
I |
DEC / 13 |
Dehydrocholic acid and its salts |
|
III |
SEP / 98 |
Delavirdine or its saltsPDL |
|
I |
DEC / 13 |
DenosumabPDL |
|
I |
DEC / 13 |
Deoxycholic acid or its saltsPDL |
when used in an injectable form
|
I |
OCT / 15 |
Dequalinium chloridePDL |
when sold for the treatment of bacterial vaginosis
|
I |
NOV / 21 |
DeracoxibPDL |
|
I |
DEC / 13 |
Derquantel or its saltsPDL |
for veterinary use
|
I |
AUG / 16 |
Deserpidine or its alkaloids or saltsPDL |
|
I |
DEC / 13 |
DesfluranePDL |
|
I |
DEC / 13 |
Desipramine or its saltsPDL |
|
I |
DEC / 13 |
Desloratadine and its salts and preparations. |
in products marketed for adult use - 12 years and older
|
U |
SEP / 05 |
Desloratadine and its salts and preparations. |
in products marketed for paediatric use - under 12 years of age |
III |
SEP / 05 |
Desmopressin or its saltsPDL |
|
I |
DEC / 13 |
Desoxyribonuclease [pancreatic dornase] |
|
II |
SEP / 98 |
Desvenlafaxine or its saltsPDL |
including but not limited to desvenlafaxine succinate
|
I |
DEC / 13 |
Detomidine or its saltsPDL |
|
I |
DEC / 13 |
Dexbrompheniramine and its salts |
|
III |
SEP / 98 |
Dexchlorpheniramine and its salts |
|
III |
SEP / 98 |
Dexrazoxane or its saltsPDL |
|
I |
DEC / 13 |
Dextromethorphan and its salts |
except in oral dosage forms in package sizes containing no more than 300mg DM base or 409.3 DM hydrobromide |
III |
AUG / 02 |
Dextromethorphan and its salts. |
in oral dosage forms in package sizes containing no more than 300 mg DM base or 409.3 DM hydrobromide |
U |
AUG / 02 |
Dextrose |
in injectable form, when used as a sclerosing agent
|
II |
SEP / 98 |
Dextrose injection |
concentrated solutions for parenteral injection |
I |
JAN / 03 |
Diazoxide or its saltsPDL |
|
I |
DEC / 13 |
Dibotermin alfaPDL |
for veterinary use
|
I |
FEB / 14 |
Dichloroacetic acidPDL |
|
I |
DEC / 13 |
Diclofenac diethylamine |
For human use - when sold as a single medicinal ingredient for topical use on the skin in concentrations greater than 1.16% and less than or equal to 2.32% for not more than 7 days - in package sizes containing greater than 2.6g of diclofenac diethylamine
|
III |
JUL / 22 |
Diclofenac diethylamine. |
For human use - when sold as a single medicinal ingredient for topical use on the skin in concentrations greater than 1.16% and less than or equal to 2.32% for not more than 7 days - in package sizes containing no more than 2.6g of diclofenac diethylamine
|
U |
JUL / 22 |
Diclofenac diethylamine.. |
For human use - when sold as a single medicinal ingredient for topical use on the skin in concentrations of not more than 1.16% for not more than 7 days
|
U |
JUL / 22 |
Diclofenac or its salts |
For human use - including (but not limited to): diclofenac diethylamine, diclofenac sodium, diclofenac potassium, except diclofenac diethylamine when sold as a single medicinal ingredient for topical use on the skin in concentrations less than or equal to 2.32% for not more than 7 days
|
I |
JUL / 22 |
Diclofenac or its saltsPDL |
For veterinary use – including (but not limited to): diclofenac sodium, diclofenac potassium
|
I |
AUG / 14 |
Dicyclomine and its salts |
except for topical use and lozenges |
II |
SEP / 98 |
Didanosine or its salts or derivativesPDL |
|
I |
DEC / 13 |
DiethylbromacetamidePDL |
|
I |
DEC / 13 |
Diethylcarbamazine or its saltsPDL |
|
I |
DEC / 13 |
Diethylpropion and any salt thereofC |
|
I |
JUN / 02 |
Diethylstilbestrol or its salts or derivativesPDL |
|
I |
DEC / 13 |
Difloxacin or its salts or derivativesPDL |
|
I |
DEC / 13 |
Diflunisal or its saltsPDL |
|
I |
DEC / 13 |
Digitalis lanata or its glycosides PDL |
|
I |
DEC / 13 |
Digitalis purpurea or its glycosides PDL |
|
I |
DEC / 13 |
Digoxin immune FabPDL |
ovine
|
I |
DEC / 13 |
Dihydroquinidine and its salts |
except phenylbarbiturate |
II |
SEP / 98 |
Dihydrostreptomycin or its salts or derivativesPDL |
For human use
|
I |
DEC / 18 |
DihydrotachysterolPDL |
for human use
|
I |
DEC / 13 |
DiiodohydroxyquinPDL |
except in preparations for topical use on the skin
|
I |
DEC / 13 |
Diiodohydroxyquin |
for topical use on the skin
|
II |
SEP / 98 |
Diltiazem or its saltsPDL |
|
I |
DEC / 13 |
Dimenhydrinate and its salts |
for parenteral use |
II |
SEP / 98 |
Dimenhydrinate and its salts. |
for oral or rectal use [Note: Pharmacists are advised that in areas where there is evidence of abuse or particular concern about abuse, dimenhydrinate products should not be located in a self-selection area of the pharmacy]. |
III |
APR / 99 |
DimercaprolPDL |
|
I |
DEC / 13 |
Dimethothiazine |
|
III |
SEP / 98 |
Dimethyl sulfoxidePDL |
For veterinary use
|
I |
DEC / 13 |
Dimethyl sulfoxidePDL |
For human use, when sold for the treatment of interstitial cystitis or scleroderma
|
I |
DEC / 13 |
DimethylfumaratePDL |
|
I |
DEC / 13 |
Dimeticone 100 cSt solution |
50% w/w for topical use in the treatment of head lice |
III |
JAN / 13 |
2,4- Dinitrophenol or its salts or derivativesPDL |
|
I |
DEC / 13 |
DinutuximabPDL |
|
I |
DEC / 18 |
Diperodon and its salts |
except for topical use |
II |
SEP / 98 |
Diphenhydramine and its salts and preparations |
for parenteral use |
II |
SEP / 98 |
Diphenhydramine and its salts and preparations. |
except for parenteral or topical use |
III |
SEP / 98 |
Diphenhydramine and its salts and preparations.. |
for topical use in concentrations of greater than 2% |
II |
MAY / 06 |
Diphenhydramine and its salts and preparations... |
for topical use in concentrations of 2% or less when sold in containers of greater than 300 mg of diphenhydramine hydrochloride |
III |
MAY / 06 |
Diphenhydramine and its salts and preparations... |
for topical use in concentrations of 2% or less when sold in containers of 300 mg or less of diphenhydramine hydrochloride |
U |
OCT / 09 |
Diphenidol or its saltsPDL |
|
I |
DEC / 13 |
Diphenylhydantoin (phenytoin) or its saltsPDL |
|
I |
SEP / 98 |
Diphenylpyraline |
|
III |
SEP / 98 |
Diphtheria toxoid |
|
II |
DEC / 98 |
Dipivefrin or its saltsPDL |
|
I |
DEC / 13 |
Diprophylline or its saltsPDL |
|
I |
DEC / 13 |
DipyridamolePDL |
|
I |
DEC / 13 |
DirithromycinPDL |
For human use
|
I |
DEC / 13 |
DirlotapidePDL |
|
I |
DEC / 13 |
Disopyramide or its saltsPDL |
|
I |
DEC / 13 |
DisulfiramPDL |
|
I |
DEC / 13 |
Dithranol |
Anthralin |
II |
SEP / 98 |
Dobutamine or its saltsPDL |
|
I |
DEC / 13 |
Docetaxel or its derivativesPDL |
including but not limited to cabazitaxel
|
I |
DEC / 13 |
Docusate and its salts |
|
U |
|
Dolasetron or its saltsPDL |
|
I |
DEC / 13 |
Dolutegravir or its saltsPDL |
|
I |
DEC / 13 |
DomperidonePDL |
|
I |
DEC / 13 |
Donepezil or its saltsPDL |
|
I |
DEC / 13 |
Dopamine or its saltsPDL |
when sold for administration by injection
|
I |
DEC / 13 |
DoravirinePDL |
|
I |
NOV / 18 |
Dornase alfaPDL |
|
I |
DEC / 13 |
Dorzolamide or its saltsPDL |
|
I |
DEC / 13 |
DostarlimabPDL |
|
I |
JAN / 22 |
Doxacurium chloridePDL |
|
I |
DEC / 13 |
DoxapramPDL |
|
I |
DEC / 13 |
Doxazosin or its saltsPDL |
|
I |
DEC / 13 |
Doxepin or its saltsPDL |
|
I |
DEC / 13 |
Doxercalciferol or its derivativesPDL |
|
I |
DEC / 13 |
Doxorubicin or its saltsPDL |
|
I |
DEC / 13 |
Doxycycline or its salts or derivativesPDL |
including but not limited to doxycycline hyclate, doxycycline monohydrate
|
I |
DEC / 13 |
Doxylamine or its salts |
except those sold for nausea and vomiting of pregnancy
|
III |
SEP / 98 |
Doxylamine or its saltsPDL |
when sold or recommended for use in the nausea or vomiting of pregnancy
|
I |
DEC / 13 |
Droperidol or its saltsPDL |
|
I |
DEC / 13 |
DrotrecoginPDL |
|
I |
DEC / 13 |
DulaglutidePDL |
|
I |
JAN / 16 |
Duloxetine or its saltsPDL |
|
I |
DEC / 13 |
DupilumabPDL |
|
I |
MAR / 18 |
DurvalumabPDL |
|
I |
DEC / 17 |
DutasteridePDL |
|
I |
DEC / 13 |
Dyclonine |
except for topical use on mucous membranes |
II |
SEP / 98 |
Dyclonine and its salts |
for topical use on mucous membranes, except lozenges |
III |
SEP / 98 |
Econazole or its saltsPDL |
|
I |
DEC / 13 |
Ecothiophate or its saltsPDL |
|
I |
DEC / 13 |
Ectylurea or its saltsPDL |
|
I |
DEC / 13 |
EculizumabPDL |
|
I |
DEC / 13 |
Edaravone or its derivatives PDL |
|
I |
NOV / 19 |
Edoxaban or its saltsPDL |
|
I |
FEB / 17 |
Edrophonium chloridePDL |
|
I |
DEC / 13 |
EfalizumabPDL |
|
I |
DEC / 13 |
EfavirenzPDL |
|
I |
DEC / 13 |
EfinaconazolePDL |
|
I |
DEC / 13 |
Eflornithine or its salts or derivativesPDL |
|
I |
DEC / 13 |
Elagolix or its salts PDL |
|
I |
DEC / 18 |
Elbasvir or its saltsPDL |
|
I |
AUG / 16 |
Eletriptan or its saltsPDL |
|
I |
DEC / 13 |
Elexacaftor or its saltsPDL |
|
I |
SEP / 21 |
Eliglustat or its saltsPDL |
|
I |
MAY / 17 |
Elosulfase alfaPDL |
|
I |
AUG / 14 |
ElotuzumabPDL |
|
I |
AUG / 16 |
Eltrombopag or its saltsPDL |
including but not limited to eltrombopag olamine
|
I |
DEC / 13 |
Eluxadoline or its saltsPDL |
|
I |
APR / 17 |
Elvitegravir or its salts or derivativesPDL |
|
I |
DEC / 18 |
Emamectin or its saltsPDL |
including but not limited to emamectin benzoate
|
I |
DEC / 13 |
EmbutramidePDL |
|
I |
DEC / 13 |
Emedastine or its saltsPDL |
|
I |
DEC / 13 |
EmicizumabPDL |
|
I |
OCT / 18 |
EmpagliflozinPDL |
|
I |
OCT / 15 |
EmtricitabinePDL |
|
I |
DEC / 13 |
EmylcamatePDL |
|
I |
DEC / 13 |
Enalapril or its salts or derivativesPDL |
including but not limited to enalapril maleate
|
I |
DEC / 13 |
Enasidenib or its saltsPDL |
|
I |
MAR / 19 |
Encephalitis vaccine (Japanese) |
|
I |
FEB / 02 |
Encorafenib or its saltsPDL |
|
I |
MAY / 21 |
EnfluranePDL |
|
I |
DEC / 13 |
Enfortumab vedotinPDL |
|
I |
NOV / 21 |
EnfuvirtidePDL |
|
I |
DEC / 13 |
Enoxaparin or its saltsPDL |
|
I |
DEC / 13 |
EnrofloxacinPDL |
|
I |
DEC / 13 |
EntacaponePDL |
|
I |
DEC / 13 |
EntecavirPDL |
|
I |
DEC / 13 |
Entrectinib or its saltsPDL |
|
I |
JUL / 20 |
EnzalutamidePDL |
|
I |
DEC / 13 |
Ephedrine and its salts |
in preparations containing more than 8 mg per unit dose, or with a label recommending more than 8 mg/dose or 32 mg/day, or labelled or implied for use exceeding 7 days, or if indicated for other than nasal congestion.
|
I |
FEB / 02 |
Ephedrine and its salts in combination products |
in preparations containing no more than 8 mg per unit dose, with a label recommending no more than 8 mg/dose or 32 mg/day and for use not more than 7 days, and indicated for nasal congestion. |
III |
APR / 06 |
Ephedrine and its salts in single entity products. |
in preparations containing no more than 8 mg per unit dose, with a label recommending no more than 8 mg/dose or 32 mg/day and for use not more than 7 days, and indicated for nasal congestion. |
II |
APR / 06 |
Epinephrine and its salts |
in injectable form, EXCEPT in pre-filled syringes intended for emergency administration in the event of anaphylactic reactions to allergens
|
I |
SEP / 99 |
Epinephrine and its salts |
in pre-filled syringes intended for emergency administration by injection in the event of anaphylactic reactions to allergens |
II |
SEP / 99 |
Epinephrine or its saltsPDL |
Epinephrine topical solution for hemostasis when sold at a concentration equal to or greater than 1 mg/mL (1:1000)
|
I |
DEC / 21 |
Epirubicine or its saltsPDL |
|
I |
DEC / 13 |
EplerenonePDL |
|
I |
DEC / 13 |
Eprosartan or its salts or derivativesPDL |
|
I |
DEC / 13 |
EpsiprantelPDL |
|
I |
DEC / 13 |
Eptifibatide or its saltsPDL |
|
I |
DEC / 13 |
EptinezumabPDL |
|
I |
MAY / 21 |
Erdafitinib or its salts PDL |
|
I |
NOV / 19 |
ErenumabPDL |
|
I |
OCT / 18 |
Ergot alkaloids or their saltsPDL |
for human use
|
I |
DEC / 13 |
Eribulin or its salts or derivativesPDL |
including but not limited to eribulin mesylate
|
I |
DEC / 13 |
Erlotinib or its saltsPDL |
|
I |
DEC / 13 |
Ertugliflozin or its derivativesPDL |
|
I |
JUL / 18 |
Erythrityl tetranitrate |
|
I |
SEP / 98 |
Erythromycin or its salts or derivativesPDL |
Including but not limited to: azithromycin, clarithromycin, gamithromycin, telithromycin, tulathromycin
|
I |
DEC / 18 |
Erythropoiesis stimulating hormonePDL |
including but not limited to erythropoietin, darbepoetin alpha, epoetin alfa
|
I |
DEC / 13 |
Escitalopram or its saltsPDL |
|
I |
DEC / 13 |
Eslicarbazepine acetatePDL |
|
I |
AUG / 14 |
Esmolol or its saltsPDL |
|
I |
DEC / 13 |
Esomeprazole or its saltsPDL |
for veterinary use
|
I |
DEC / 13 |
Esomeprazole or its salts |
For human use, when sold for the 14-day treatment for frequent heartburn at a daily dose of 20 mg, in package sizes of no more than 280 mg of esomeprazole
|
III |
NOV / 18 |
Esomeprazole or its salts |
For human use, including but not limited to esomeprazole magnesium, EXCEPT when sold for the 14-day treatment for frequent heartburn at a daily dose of 20 mg, in package sizes of no more than 280 mg of esomeprazole
|
I |
NOV / 18 |
Estramustine or its saltsPDL |
|
I |
DEC / 13 |
EtanerceptPDL |
|
I |
DEC / 13 |
Ethacrynic acidPDL |
|
I |
DEC / 13 |
Ethambutol or its saltsPDL |
|
I |
DEC / 13 |
Ethanolamine oleate |
|
II |
SEP / 98 |
EthchlorvynolTS |
|
I |
SEP / 98 |
EthinamateTS |
|
I |
SEP / 98 |
Ethionamide or its saltsPDL |
|
I |
DEC / 13 |
Ethoheptazine and its salts |
|
II |
SEP / 98 |
Ethomoxane or its saltsPDL |
|
I |
DEC / 13 |
Ethotoin or its saltsPDL |
|
I |
DEC / 13 |
Ethyl Chloride |
except in trace amounts |
II |
SEP / 98 |
Ethyl trichloramatePDL |
|
I |
DEC / 13 |
Ethylpapaverine and its salts |
|
I |
SEP / 98 |
Etidronic acid or its saltsPDL |
|
I |
DEC / 13 |
Etodolac or its salts or derivativesPDL |
|
I |
DEC / 13 |
Etomidate or its salts PDL |
|
I |
SEP / 20 |
Etoposide or its derivativesPDL |
|
I |
DEC / 13 |
Etravirine or its saltsPDL |
|
I |
DEC / 13 |
EtretinatePDL |
|
I |
DEC / 13 |
Etryptamine and its salts |
|
I |
SEP / 98 |
Etymemazine or its saltsPDL |
|
I |
DEC / 13 |
EvolocumabPDL |
|
I |
JAN / 16 |
ExemestanePDL |
|
I |
DEC / 13 |
Exenatide or its saltsPDL |
|
I |
DEC / 13 |
EzetimibePDL |
|
I |
DEC / 13 |
Ezogabine or its salts or derivativesPDL |
|
I |
DEC / 13 |
Famciclovir or its saltsPDL |
|
I |
DEC / 13 |
Famotidine and its salts. |
For human use - when sold in concentrations of 20 mg or less per oral dosage unit and indicated for the treatment of heartburn, in package sizes containing more than 600 mg of famotidine.
|
III |
MAY / 08 |
Famotidine and its salts.. |
For human use - when sold in concentrations of 20 mg or less per oral dosage unit and indicated for the treatment of heartburn, in package sizes containing no more than 600 mg of famotidine.
|
U |
FEB / 07 |
Famotidine or its saltsPDL |
For veterinary use.
|
I |
DEC / 13 |
Famotidine or its saltsPDL |
For human use - except when sold in concentrations of 20 mg or less per oral dosage unit and indicated for the treatment of heartburn.
|
I |
DEC / 13 |
Fampridine or its salts or derivativesPDL |
|
I |
DEC / 13 |
Febuxostat or its salts or derivativesPDL |
|
I |
DEC / 13 |
Fedratinib or its salts PDL |
|
I |
SEP / 20 |
Felodipine or its saltsPDL |
|
I |
DEC / 13 |
Fencamfamin and any salt thereofTS |
|
I |
NOV / 20 |
Fenetylline and any salt thereofC |
|
I |
JAN / 03 |
Fenfluramine or its saltsPDL |
Including but not limited to dexfenfluramine.
|
I |
DEC / 13 |
FenofibratePDL |
|
I |
DEC / 13 |
Fenoprofen or its saltsPDL |
|
I |
DEC / 13 |
Fenoterol or its saltsPDL |
|
I |
DEC / 13 |
FenproporexTS |
|
I |
JUN / 02 |
Fentanyls, their salts, derivatives, and analogues and salts of derivatives and analoguesN |
Including: Acetyl-α-methylfentanyl, Alfentanil, Carfentanil, p-Fluorofentanyl, Fentanyl, ß-Hydroxyfentanyl, ß-Hydroxy-3-methylfentanyl, α-Methylfentanyl, α-Methylthiofentanyl, 3-Methylfentanyl, 3-Methylthiofentanyl, Remifentanil, Sufentanil, Thiofentanyl, 4-Anilino-N-phenethylpiperidine (ANPP), its derivatives and analogues and salts of derivatives and analogues
|
I |
JUN / 02 |
Fesoterodine or its saltsPDL |
Including but not limited to fesoterodine fumarate.
|
I |
DEC / 13 |
Fexofenadine hydrochloride |
in products marketed for adult use (12 years and older) |
U |
APR / 07 |
Fexofenadine hydrochloride. |
in products marketed for paediatric use (under 12 years of age) |
III |
APR / 07 |
Fibrin |
|
II |
SEP / 98 |
Fibrinolysin |
|
II |
SEP / 98 |
Fidaxomicin or its derivativesPDL |
|
I |
DEC / 13 |
FilgrastimPDL |
|
I |
DEC / 13 |
Finafloxacin or its salts or its derivativesPDL |
|
I |
AUG / 16 |
FinasteridePDL |
|
I |
DEC / 13 |
Fingolimod or its salts or derivativesPDL |
Including but not limited to fingolimod hydrochloride.
|
I |
DEC / 13 |
FirocoxibPDL |
|
I |
DEC / 13 |
Flavoxate or its saltsPDL |
|
I |
DEC / 13 |
Flecainide or its saltsPDL |
|
I |
DEC / 13 |
Fleroxacin or its salts or derivativesPDL |
|
I |
DEC / 13 |
Flibanserin or its saltsPDL |
|
I |
MAY / 18 |
FloctafeninePDL |
|
I |
DEC / 13 |
Florfenicol or its derivativesPDL |
|
I |
DEC / 13 |
FluconazolePDL |
For human use - except when sold in a concentration of 150 mg per oral dosage unit and indicated for the treatment of vaginal candidiasis.
|
I |
DEC / 13 |
Fluconazole |
For human use - when sold in a concentration of 150 mg per oral dosage unit and indicated for the treatment of vaginal candidiasis, in package sizes containing no more than 150 mg of fluconazole.
|
III |
MAR / 10 |
FluconazolePDL |
For veterinary use.
|
I |
DEC / 13 |
FlucytosinePDL |
|
I |
DEC / 13 |
Fludarabine or its salts or derivativesPDL |
|
I |
DEC / 13 |
Flumazenil |
|
I |
SEP / 98 |
Flunarizine or its saltsPDL |
|
I |
DEC / 13 |
Flunitrazepam and any salts or derivatives thereofTS |
|
I |
JUN / 02 |
Flunixin or its salts or derivativesPDL |
Including but not limited to flunixin meglumine.
|
I |
DEC / 13 |
Fluoride or its salts (see sodium fluoride)PDL |
For human use - in solid oral dosage forms containing more than 1 mg of fluoride ion.
|
I |
DEC / 13 |
Fluorouracil or its derivativesPDL |
Including but not limited to capecitabine, tegafur.
|
I |
DEC / 13 |
Fluoxetine or its saltsPDL |
|
I |
DEC / 13 |
Flupentixol or its salts or derivativesPDL |
Including but not limited to flupentixol decanoate.
|
I |
DEC / 13 |
Fluphenazine or its saltsPDL |
|
I |
DEC / 13 |
FluralanerPDL |
|
I |
JUN / 14 |
Flurbiprofen or its saltsPDL |
|
I |
DEC / 13 |
FluspirilenePDL |
|
I |
DEC / 13 |
FlutamidePDL |
|
I |
DEC / 13 |
Fluticasone propionate |
When sold for the treatment of allergic rhinitis in a nasal spray that delivers 50 mcg/spray for those 18 years of age and older, in package sizes containing more than 360 metered sprays.
|
II |
JAN / 20 |
Fluticasone propionate |
When sold for the treatment of allergic rhinitis in a nasal spray that delivers 50 mcg/spray for those 18 years of age and older, in package sizes containing no more than 360 metered sprays.
|
III |
JAN / 20 |
Fluvastatin or its salts or derivativesPDL |
|
I |
DEC / 13 |
Fluvoxamine or its saltsPDL |
|
I |
DEC / 13 |
Folic acidPDL |
For human use - in oral dosage form containing more than 1.0 milligram of folic acid per dosage form or, where the largest recommended daily dosage shown on the label would, if consumed by a person, result in the daily intake by that person of more than 1.0 milligram of folic acid.
|
I |
DEC / 13 |
Follicle stimulating hormonePDL |
including but not limited to: follitropin alpha, follitropin beta, follitropin delta
|
I |
DEC / 13 |
Fomepizole or its saltsPDL |
|
I |
DEC / 13 |
Fondaparinux sodiumPDL |
|
I |
DEC / 13 |
Formestane or its derivativesPDL |
|
I |
DEC / 13 |
Formoterol or its saltsPDL |
|
I |
DEC / 13 |
Foscarnet sodiumPDL |
|
I |
DEC / 13 |
Fosfomycin or its saltsPDL |
|
I |
DEC / 13 |
Fosinopril or its saltsPDL |
|
I |
DEC / 13 |
Fosphenytoin or its saltsPDL |
|
I |
DEC / 13 |
Fostamatinib or its saltsPDL |
|
I |
DEC / 20 |
Fostemsavir or its saltsPDL |
|
I |
JAN / 22 |
Fractar |
|
III |
SEP / 98 |
Framycetin or its salts or derivativesPDL |
For human use.
|
I |
DEC / 13 |
FremanezumabPDL |
|
I |
JUL / 20 |
Frovatriptan or its saltsPDL |
|
I |
DEC / 13 |
FrunevetmabPDL |
For veterinary use
|
I |
SEP / 21 |
FulvestrantPDL |
|
I |
DEC / 13 |
Furaltadone or its saltsPDL |
For human use.
|
I |
DEC / 13 |
Furazolidone or its saltsPDL |
For human use.
|
I |
DEC / 13 |
FurosemidePDL |
For human use.
|
I |
DEC / 13 |
Fusidic acid or its saltsPDL |
|
I |
DEC / 13 |
Gabapentin or its salts or derivativesPDL |
|
I |
DEC / 13 |
Galantamine or its salts or derivativesPDL |
|
I |
DEC / 13 |
Galcanezumab PDL |
|
I |
OCT / 19 |
Gallamine triethiodidePDL |
|
I |
DEC / 13 |
Gallium or its saltsPDL |
|
I |
DEC / 13 |
GalsulfasePDL |
|
I |
DEC / 13 |
Gamithromuycin PDL |
|
I |
DEC / 13 |
Ganciclovir or its saltsPDL |
|
I |
DEC / 13 |
Ganirelix or its salts or derivativesPDL |
Including but not limited to ganirelix acetate.
|
I |
DEC / 13 |
Gatifloxacin or its salts or derivativesPDL |
|
I |
DEC / 13 |
GefitinibPDL |
|
I |
DEC / 13 |
Gemcitabine or its saltsPDL |
|
I |
DEC / 13 |
Gemfibrozil or its saltsPDL |
|
I |
DEC / 13 |
Gemifloxacin or its saltsPDL |
|
I |
DEC / 13 |
Gemtuzumab ozogamicin PDL |
|
I |
FEB / 20 |
Gentamicin or its salts or derivativesPDL |
Including but not limited to netilmicin.
|
I |
DEC / 13 |
Gentian Violet |
|
II |
DEC / 01 |
Gilteritinib or its saltsPDL |
|
I |
FEB / 20 |
Givosiran or its saltsPDL |
|
I |
DEC / 20 |
Glasdegib or its saltsPDL |
|
I |
JUL / 20 |
Glatiramer or its saltsPDL |
|
I |
DEC / 13 |
GlecaprevirPDL |
|
I |
SEP / 17 |
GliclazidePDL |
|
I |
DEC / 13 |
GlimepiridePDL |
|
I |
DEC / 13 |
GlipizidePDL |
|
I |
DEC / 13 |
Glucagon |
|
II |
SEP / 98 |
GlutethimideC |
|
I |
SEP / 98 |
Glyburide or its salts or derivativesPDL |
|
I |
DEC / 13 |
Glyceroargentinate |
|
III |
SEP / 98 |
Glycopyrrolate or its salts |
except glycopyrronium bromide, including but not limited to glycopyrrolate, when used orally or for inhalation
|
II |
DEC / 17 |
Glycopyrronium bromidePDL |
Including but not limited to glycopyrrolate, when used orally or for inhalation.
|
I |
DEC / 17 |
Gold or its salts or derivativesPDL |
Including but not limited to aurothioglucose, auranofin and sodium aurothiomalate, when sold for administration by injection.
|
I |
DEC / 13 |
GolimumabPDL |
|
I |
DEC / 13 |
Gonadorelin or its saltsPDL |
|
I |
DEC / 13 |
Gonadotropin releasing factor or its analoguesPDL |
For veterinary use.
|
I |
DEC / 13 |
Gonadotropin, chorionic (human)PDL |
|
I |
DEC / 13 |
Gonadotropins, serum (human)PDL |
|
I |
DEC / 13 |
Goserelin or its saltsPDL |
|
I |
DEC / 13 |
Gramicidin and its salts |
for topical use |
U |
|
Gramicidin and its salts and derivatives |
for ophthalmic use |
III |
JUN / 06 |
Granisetron or its saltsPDL |
|
I |
DEC / 13 |
Grapiprant or its saltsPDL |
For veterinary use
|
I |
FEB / 19 |
GrazoprevirPDL |
|
I |
AUG / 16 |
Grepafloxacin or its salts or derivativesPDL |
|
I |
DEC / 13 |
Griseofulvin or its salts or derivativesPDL |
For human use.
|
I |
DEC / 13 |
Guaifenesin |
|
U |
|
Guanethidine or its saltsPDL |
|
I |
DEC / 13 |
Guanfacine or its salts or derivativesPDL |
|
I |
DEC / 13 |
GuselkumabPDL |
|
I |
MAR / 18 |
Haemophilus influenzae type B vaccine |
|
II |
DEC / 98 |
Halofantrine or its saltsPDL |
|
I |
DEC / 13 |
Halofuginone or its saltsPDL |
For veterinary use.
|
I |
MAY / 18 |
HaloperidolPDL |
|
I |
DEC / 13 |
Haloprogin |
|
III |
SEP / 98 |
HalothanePDL |
|
I |
DEC / 13 |
HeminPDL |
|
I |
AUG / 18 |
Heparin and its salts |
in injectable form
|
II |
SEP / 99 |
Hepatitis A vaccine |
|
I |
FEB / 02 |
Hepatitis B Adult vaccine |
|
I |
FEB / 02 |
Hepatitis B Pediatric vaccine |
|
II |
DEC / 98 |
Hepatitis B immune globulin |
|
I |
FEB / 02 |
Hetacillin or its salts or derivativesPDL |
For veterinary use.
|
I |
DEC / 13 |
Hetastarch or its derivativesPDL |
|
I |
DEC / 13 |
Hexachlorophene or its saltsPDL |
|
I |
DEC / 13 |
Hexacyclonate sodiumPDL |
|
I |
DEC / 13 |
Hexamethonium or its saltsPDL |
|
I |
DEC / 13 |
Histrelin or its saltsPDL |
|
I |
DEC / 13 |
Homatropine and its salts |
for oral use in concentrations of 2 mg or less per dosage unit |
II |
SEP / 98 |
Homatropine and its salts |
for ophthalmic or parenteral use or in preparations for oral use containing more than 2 mg per dosage unit |
I |
SEP / 98 |
Human insulin |
|
II |
SEP / 98 |
Hyaluronic acid or its saltsPDL |
For veterinary use - when sold or recommended for administration by intra-articular injection to horses.
|
I |
DEC / 13 |
Hydralazine or its saltsPDL |
|
I |
DEC / 13 |
Hydrocortisone aceponatePDL |
For veterinary use.
|
I |
DEC / 13 |
Hydroquinone or its derivativesPDL |
When sold in a concentration greater than 2% in preparations for topical use on the skin.
|
I |
JUN / 19 |
Hydroxocobalamin or its saltsPDL |
When recommended as an antidote for cyanide poisoning.
|
I |
DEC / 13 |
4- Hydroxybutanoic acid (GHB) and any salt thereofC |
|
I |
NOV / 20 |
Hydroxychloroquine or its saltsPDL |
|
I |
DEC / 13 |
4- Hydroxycoumarin or its derivativesPDL |
Including but not limited to acenocoumarol when sold or recommended as anticoagulants.
|
I |
DEC / 13 |
Hydroxyephedrine and its salts |
|
II |
SEP / 98 |
HydroxyureaPDL |
|
I |
DEC / 13 |
Hydroxyzine or its salts or derivativesPDL |
Including but not limited to cetirizine and hydroxyzine hydrochloride. cetirizine or its salts when sold in concentration greater than 8.5 milligrams cetirizine per unit dose.
|
I |
DEC / 13 |
Hyoscine (scopolamine) |
in injectable form
|
II |
AUG / 16 |
Hyoscine butylbromidePDL |
When recommended for parenteral use.
|
I |
AUG / 16 |
Hyoscine butylbromide (Butylscopolamine bromide) |
except when recommended for injectable use
|
II |
AUG / 16 |
IbafloxacinPDL |
|
I |
DEC / 13 |
Ibandronic acid or its saltsPDL |
|
I |
DEC / 13 |
Ibogaine or its salts or derivatives or analoguesPDL |
|
I |
MAY / 17 |
Ibrutinib or its saltsPDL |
|
I |
DEC / 14 |
Ibuprofen or its saltsPDL |
For human use - except when sold in an oral dosage form that provides 400 mg or less per dosage unit or in a modified-release oral dosage form that provides 600 mg or less per dosage unit.
|
I |
AUG / 16 |
Ibuprofen or its saltsPDL |
For veterinary use.
|
I |
DEC / 13 |
Ibuprofen or its salts. |
when sold in an immediate release dosage form containing 400 mg or less per oral dosage unit (in package sizes exceeding 18,000 mg) |
III |
FEB / 12 |
Ibuprofen or its salts.. |
when sold in a modified-release oral dosage form that provides 600 mg or less per dosage unit
|
III |
AUG / 16 |
Ibuprofen or its salts... |
when sold in an immediate release dosage form containing 400 mg or less per oral dosage unit (in package sizes of up to 18,000 mg) |
U |
FEB / 12 |
Ibutilide or its salts or derivativesPDL |
|
I |
DEC / 13 |
Icatibant or its saltsPDL |
Including but not limited to Icatibant acetate.
|
I |
AUG / 14 |
Icosapent ethylPDL |
For human use: when sold or recommended to reduce the risk of cardiovascular events in statin-treated patients with elevated triglycerides.
|
I |
FEB / 20 |
Icosapent ethylPDL |
For veterinary use.
|
I |
FEB / 20 |
Idarubicin or its saltsPDL |
|
I |
DEC / 13 |
IdarucizumabPDL |
|
I |
AUG / 16 |
IdebenonePDL |
|
I |
DEC / 13 |
Idecabtagene vicleucelPDL |
|
I |
JUL / 21 |
IdelalisibPDL |
|
I |
MAY / 15 |
IdoxuridinePDL |
|
I |
DEC / 13 |
IdursulfasePDL |
|
I |
DEC / 13 |
IfosfamidePDL |
|
I |
DEC / 13 |
Imatinib or its saltsPDL |
|
I |
DEC / 13 |
ImdevimabPDL |
|
I |
JUN / 21 |
Imidapril or its saltsPDL |
|
I |
DEC / 13 |
ImiglucerasePDL |
|
I |
DEC / 13 |
Imipramine or its saltsPDL |
|
I |
DEC / 13 |
Imiquimod or its saltsPDL |
|
I |
DEC / 13 |
Immune globulin products |
|
I |
FEB / 02 |
Immunogenic substancesPDL |
When recommended for sublingual use, including but not limited to: anthoxanthium odoratum L. (sweet vernal grass), betula verrucosa (white birch), dactylis glomerata L. (cocksfoot), lolium perenne L. (rye grass), phleum pratense L. (timothy grass), poa pratense L. (meadow grass).
|
I |
JUL / 20 |
Inclisiran or its saltsPDL |
|
I |
SEP / 21 |
Indacaterol or its salts or derivativesPDL |
|
I |
DEC / 13 |
Indapamide or its saltsPDL |
|
I |
DEC / 13 |
Indinavir or its saltsPDL |
|
I |
DEC / 13 |
IndomethacinPDL |
|
I |
DEC / 13 |
Infigratinib or its saltsPDL |
|
I |
OCT / 21 |
InfliximabPDL |
|
I |
DEC / 13 |
Influenza vaccine |
|
II |
DEC / 98 |
Ingenol mebutate or its derivativesPDL |
|
I |
DEC / 13 |
Inhaled human insulinPDL |
|
I |
DEC / 13 |
InosiplexPDL |
|
I |
DEC / 13 |
Inotersen or its saltsPDL |
|
I |
NOV / 18 |
Inotuzumab ozogamicinPDL |
|
I |
MAY / 18 |
Insulin |
|
II |
SEP / 98 |
InterferonPDL |
|
I |
DEC / 13 |
Iodinated glycerol |
|
II |
SEP / 98 |
Iodochlorhydroxyquin |
for topical use |
II |
SEP / 98 |
IodochlorohydroxyquinPDL |
For human use - except in preparations for topical use on the skin.
|
I |
DEC / 13 |
IodochlorohydroxyquinPDL |
For veterinary use.
|
I |
DEC / 13 |
IpilimumabPDL |
|
I |
DEC / 13 |
Ipratropium or its saltsPDL |
|
I |
DEC / 13 |
Iproniazid or its saltsPDL |
|
I |
DEC / 13 |
Irbesartan or its saltsPDL |
|
I |
DEC / 13 |
Irinotecan or its saltsPDL |
|
I |
DEC / 13 |
Iron derivativesPDL |
For veterinary use - including but not limited to ferumoxytol, for all routes of administration but parenteral.
|
I |
DEC / 13 |
Iron derivativesPDL |
For human use - including but not limited to ferumoxytol, iron isomaltoside 1000, for parenteral use only.
|
I |
DEC / 13 |
IsatuximabPDL |
|
I |
JUL / 20 |
Isavuconazole or its saltsPDL |
|
I |
FEB / 19 |
Isocarboxazid or its saltsPDL |
|
I |
DEC / 13 |
IsofluranePDL |
|
I |
DEC / 13 |
IsoniazidPDL |
|
I |
DEC / 13 |
Isopropamide and its salts |
|
I |
SEP / 98 |
Isopropyl myristate in concentration of 50% |
for use in the treatment of head lice
|
III |
JUL / 07 |
Isoproterenol (Isoprenaline) or its saltsPDL |
|
I |
DEC / 13 |
Isosorbide and its salts |
|
I |
SEP / 98 |
Isotretinoin or its saltsPDL |
|
I |
DEC / 13 |
Isoxsuprine or its saltsPDL |
|
I |
DEC / 13 |
Isradipine or its saltsPDL |
|
I |
DEC / 13 |
Itraconazole or its saltsPDL |
|
I |
DEC / 13 |
Ivabradine or its salts or derivativesPDL |
|
I |
FEB / 17 |
Ivacaftor or its derivativesPDL |
|
I |
DEC / 13 |
Ixazomib or its derivativesPDL |
|
I |
NOV / 16 |
IxekizumabPDL |
|
I |
AUG / 16 |
Kanamycin or its salts or derivativesPDL |
For human use.
|
I |
DEC / 13 |
Ketanserin or its saltsPDL |
|
I |
DEC / 13 |
Ketoconazole and its salts. |
as a shampoo |
U |
|
Ketoconazole or its saltsPDL |
For veterinary use
|
I |
DEC / 13 |
Ketoconazole or its saltsPDL |
For human use - except in preparations for topical use as a shampoo.
|
I |
DEC / 13 |
Ketoprofene or its saltsPDL |
|
I |
DEC / 13 |
Ketorolac or its saltsPDL |
|
I |
DEC / 13 |
Ketotifen or its saltsPDL |
|
I |
DEC / 13 |
L-TryptophanPDL |
when sold, a) for human use in oral dosage form at a concentration of more than 220 mg per dosage unit or per daily dose, as a single ingredient or in combination with other ingredients; or b) for human or veterinary use as a single ingredient intended for any route of administration other than oral
|
I |
DEC / 13 |
Labetalol or its saltsPDL |
|
I |
DEC / 13 |
Lacosamide or its derivativesPDL |
|
I |
DEC / 13 |
Lactic acidPDL |
When recommended for parenteral use as a tissue sclerosing agent.
|
I |
DEC / 13 |
Lactulose |
|
III |
SEP / 98 |
Lamivudine or its saltsPDL |
|
I |
DEC / 13 |
Lamotrigine or its saltsPDL |
|
I |
DEC / 13 |
LanadelumabPDL |
|
I |
NOV / 18 |
Lanreotide or its saltsPDL |
|
I |
DEC / 13 |
Lansoprazole or its saltsPDL |
|
I |
DEC / 13 |
Lanthanum saltsPDL |
For human use - when sold for the treatment of hyperphosphatemia.
|
I |
DEC / 13 |
Lapatinib or its saltsPDL |
|
I |
DEC / 13 |
LaronidasePDL |
|
I |
DEC / 13 |
Larotrectinib or its salts PDL |
|
I |
OCT / 19 |
Ledipasvir or its saltsPDL |
|
I |
DEC / 14 |
Lefamulin or its salts PDL |
|
I |
SEP / 20 |
Lefetamine, its salts, derivatives and isomers and salts of derivatives and isomersC |
|
I |
JAN / 03 |
Leflunomide or its salts or derivativesPDL |
Including but not limited to teriflunomide.
|
I |
DEC / 13 |
Lemborexant or its saltsPDL |
|
I |
DEC / 20 |
LenalidomidePDL |
|
I |
DEC / 13 |
Lenvatinib or its saltsPDL |
|
I |
AUG / 16 |
Letermovir or its saltsPDL |
|
I |
DEC / 17 |
LetrozolePDL |
|
I |
DEC / 13 |
Leucovorin or its saltsPDL |
|
I |
DEC / 13 |
Leuprolide or its saltsPDL |
|
I |
DEC / 13 |
Levallorphane and its salts |
|
I |
SEP / 98 |
Levamisole or its saltsPDL |
For human use.
|
I |
DEC / 13 |
Levargorphane and its salts |
|
II |
SEP / 98 |
LevetiracetamPDL |
|
I |
DEC / 13 |
Levobunolol or its saltsPDL |
|
I |
DEC / 13 |
Levocabastine or its salts or derivativesPDL |
|
I |
DEC / 13 |
Levocarnitine or its salts or derivativesPDL |
When sold for the treatment of primary or secondary levocarnitine deficiency.
|
I |
DEC / 13 |
Levodopa or its saltsPDL |
|
I |
DEC / 13 |
Levomilnacipran or its saltsPDL |
|
I |
JUN / 15 |
Levonordefrine |
|
II |
SEP / 98 |
Levonorgestrel |
when sold in concentrations of 1.5 mg or less per oral dosage unit (except when labelled to be taken as a single dose of 1.5 mg and in package sizes containing no more than 1.5 mg levonorgestrel, packaged and labelled for emergency contraception.) |
II |
MAY / 15 |
Levonorgestrel. |
when sold in concentrations of 1.5 mg or less per oral dosage unit to be taken as a single dose of 1.5 mg, packaged and labelled for emergency contraception, in package sizes containing no more than 1.5 mg of levonorgestrel |
III |
MAY / 15 |
LidocainePDL |
For human use - when in a preparation containing an equal amount of tetracaine and recommended for topical use on the skin, in concentrations of 7% or higher.
|
I |
FEB / 14 |
Lidocaine and its salts |
for ophthalmic or parenteral use, or topical use on mucous membranes, except lozenges |
II |
SEP / 98 |
Lidocaine and its salts. |
for otic use
|
III |
JUN / 06 |
Lidocaine and its salts.. |
for topical use on the skin, including lozenges [except when in a preparation containing an equal amount of tetracaine and recommended for topical use on the skin, in concentrations of 7% or higher]
|
U |
FEB / 14 |
Lidocaine and prilocaine |
eutectic mixture |
III |
FEB / 99 |
Lifitegrast or its saltsPDL |
|
I |
MAR / 18 |
Linaclotide or its salts or derivativesPDL |
|
I |
DEC / 13 |
Linagliptin or its salts or derivativesPDL |
|
I |
DEC / 13 |
Lincomycin or its salts or derivativesPDL |
Including but not limited to: Clindamycin
|
I |
DEC / 18 |
Lindane |
|
II |
SEP / 98 |
Linezolid or its saltsPDL |
|
I |
DEC / 13 |
Liothyronine or its saltsPDL |
For human use.
|
I |
DEC / 13 |
Lipid solutions in injectable form for parenteral nutrition |
|
I |
JAN / 03 |
Liraglutide or its saltsPDL |
|
I |
DEC / 13 |
Lisinopril or its salts or derivativesPDL |
|
I |
DEC / 13 |
Lithium or its saltsPDL |
|
I |
DEC / 13 |
Lixisenatide or its saltsPDL |
|
I |
JUN / 17 |
Lodoxamide or its salts or derivativesPDL |
Including but not limited to Lodoxamide tromethamine.
|
I |
DEC / 13 |
Lomefloxacin or its saltsPDL |
|
I |
DEC / 13 |
Lomitapide or its saltsPDL |
|
I |
FEB / 14 |
LomustinePDL |
|
I |
DEC / 13 |
Loperamide and its salts |
in products marketed for adult use (12 years and older) |
U |
APR / 07 |
Loperamide and its salts. |
in products marketed for paediatric use (under 12 years of age) |
II |
APR / 07 |
LopinavirPDL |
|
I |
DEC / 13 |
Loratadine and its salts and preparations |
in products marketed for paediatric use - under 12 years of age |
III |
OCT / 02 |
Loratadine and its salts and preparations. |
in products marketed for adult use - 12 years and older |
U |
OCT / 02 |
Lorlatinib or its salts PDL |
|
I |
MAR / 19 |
Losartan or its saltsPDL |
|
I |
DEC / 13 |
Losoxantrone or its saltsPDL |
|
I |
DEC / 13 |
LotilanerPDL |
For veterinary use.
|
I |
MAR / 18 |
LovastatinPDL |
Except in oral dosage form that provides 1 milligram (mg) or less per daily dose.
|
I |
DEC / 14 |
Loxapine or its saltsPDL |
|
I |
DEC / 13 |
Lumacaftor or its salts or derivativesPDL |
|
I |
AUG / 16 |
Lumasiran or its saltsPDL |
|
I |
JUN / 22 |
LumiracoxibPDL |
|
I |
DEC / 13 |
Lurasidone or its saltsPDL |
|
I |
DEC / 13 |
Lurbinectedin or its salts or derivativesPDL |
|
I |
OCT / 21 |
LuspaterceptPDL |
|
I |
DEC / 20 |
Lutropin alfaPDL |
|
I |
DEC / 13 |
Lyme Disease vaccine |
|
I |
FEB / 02 |
Macitentan or its derivativesPDL |
|
I |
DEC / 13 |
Magnesium glutamate hydrobromidePDL |
|
I |
DEC / 13 |
Magnesium sulfate |
in injectable form
|
II |
SEP / 98 |
Magnesium sulfate in injectable form for parenteral nutrition |
|
I |
JAN / 03 |
Manganese and its salts |
In injectable form for parenteral nutrition.
|
I |
JAN / 03 |
Mannitol PDL |
When sold and recommended for use as a diagnostic agent for the assessment of bronchial hyperresponsiveness.
|
I |
OCT / 19 |
Maprotiline or its saltsPDL |
|
I |
DEC / 13 |
MaravirocPDL |
|
I |
DEC / 13 |
Marbofloxacin or its salts or derivativesPDL |
|
I |
DEC / 13 |
Maropitant or its saltsPDL |
|
I |
DEC / 13 |
MazindolTS |
|
I |
SEP / 98 |
Measles vaccine |
|
II |
DEC / 98 |
MebendazolePDL |
For human use.
|
I |
DEC / 13 |
MebendazolePDL |
For veterinary use - when sold to treat dogs only.
|
I |
DEC / 13 |
Mecamylamine or its saltsPDL |
|
I |
DEC / 13 |
MecaserminPDL |
|
I |
MAY / 21 |
Mechlorethamine or its saltsPDL |
|
I |
DEC / 13 |
Mecillinam or its salts or derivativesPDL |
For veterinary use.
|
I |
DEC / 13 |
Meclizine and its salts. |
when sold in concentrations of 25 mg or less per dosage unit
|
III |
MAY / 00 |
Meclizine or its saltsPDL |
For human use - when sold in concentrations greater than 25 mg per dosage unit.
|
I |
DEC / 13 |
Meclofenamic acid or its saltsPDL |
|
I |
DEC / 13 |
Mecloqualone and any salt thereofC |
|
I |
JAN / 03 |
Medetomidine or its saltsPDL |
|
I |
DEC / 13 |
Mefenamic acid or its saltsPDL |
|
I |
DEC / 13 |
Mefenorex and any salt thereofTS |
|
I |
JUN / 02 |
Mefloquine or its salts or derivativesPDL |
|
I |
DEC / 13 |
Megestrol or its saltsPDL |
|
I |
DEC / 13 |
Melanoma therapeutic vaccinePDL |
|
I |
DEC / 13 |
Melarsomine or its saltsPDL |
For veterinary use - when sold for the treatment of heartworm in dogs.
|
I |
DEC / 13 |
Melarsomine or its saltsPDL |
For human use
|
I |
DEC / 13 |
Meloxicam or its salts or derivativesPDL |
|
I |
DEC / 13 |
MelphalanPDL |
|
I |
DEC / 13 |
Memantine or its saltsPDL |
|
I |
DEC / 13 |
Meningococcus vaccine |
|
II |
MAR / 01 |
Menotropins (human)PDL |
|
I |
DEC / 13 |
Mepacrine or its saltsPDL |
|
I |
DEC / 13 |
Mepazine or its saltsPDL |
|
I |
DEC / 13 |
MephenoxalonePDL |
|
I |
DEC / 13 |
Mephentermine or its saltsPDL |
|
I |
DEC / 13 |
Mepivacaine and its salts |
for topical use on mucous membranes, except lozenges |
III |
SEP / 98 |
Mepivacaine and its salts |
for ophthalmic or parenteral use |
II |
SEP / 98 |
MepolizumabPDL |
|
I |
AUG / 16 |
MeprobamateTS |
|
I |
SEP / 98 |
Mepyramine |
see pyrilamine |
U |
|
MercaptopurinePDL |
|
I |
DEC / 13 |
MesnaPDL |
|
I |
DEC / 13 |
Mesocarb and any salt thereofC |
|
I |
JAN / 03 |
Mesoridazine or its saltsPDL |
|
I |
DEC / 13 |
MetaldehydePDL |
|
I |
DEC / 13 |
Metamizole (dipyrone) or its saltsPDL |
For veterinary use
|
I |
JUL / 22 |
Metaraminol bitartrate |
|
I |
SEP / 98 |
Metathoheptazine and its salts |
|
II |
SEP / 98 |
Metformin or its salts or derivativesPDL |
|
I |
DEC / 13 |
Methacholine chloridePDL |
|
I |
DEC / 13 |
Methadols, their salts, derivatives and salts of derivativesN |
Including: Acetylmethadol, Alphacetylmethadol, Alphamethadol, Betacetylmethadol, Betamethadol, Dimepheptanol, Noracymethadol
|
I |
JUN / 02 |
Methantheline and its salts |
|
II |
SEP / 98 |
Methaqualone and any salt thereofC |
|
I |
JUN / 02 |
Methazolamide or its saltsPDL |
|
I |
DEC / 13 |
Methdilazine and its salts |
|
II |
SEP / 98 |
Metheptazine and its salts |
|
II |
SEP / 98 |
Methicillin or its salts or derivativesPDL |
For veterinary use.
|
I |
DEC / 13 |
MethimazolePDL |
|
I |
DEC / 13 |
MethisazonePDL |
|
I |
DEC / 13 |
Methocarbamol |
for parenteral use |
II |
SEP / 98 |
Methocarbamol. |
except for parenteral use |
III |
SEP / 98 |
Methoin (Mephenytoin) or its saltsPDL |
|
I |
DEC / 13 |
Methotrexate or its saltsPDL |
|
I |
DEC / 13 |
Methotrimeprazine or its saltsPDL |
|
I |
DEC / 13 |
Methoxamine or its saltsPDL |
|
I |
DEC / 13 |
MethoxsalenPDL |
|
I |
DEC / 13 |
Methoxy polyethylene glycol-epoetin betaPDL |
|
I |
DEC / 13 |
MethoxyfluranePDL |
|
I |
MAY / 18 |
Methyldopa or its saltsPDL |
|
I |
DEC / 13 |
Methylene Blue |
for parenteral use |
II |
SEP / 98 |
Methylnaltrexone or its saltsPDL |
Including but not limited to methylnaltrexone bromide.
|
I |
JUN / 15 |
MethylparafynolPDL |
|
I |
DEC / 13 |
Methylphenidate, its salts, derivatives, isomers and analogues and salts of derivatives, isomers and analoguesC |
Including: Ethylphenidate; Isopropylphenidate; Propylphenidate; 3,4-Dichloromethylphenidate; 4-Methylmethylphenidate; 4-Fluoromethylphenidate;
Methylnaphthidate; Ethylnaphthidate
|
I |
JUN / 02 |
MethyprylonTS |
|
I |
SEP / 98 |
Methysergide or its salts or derivativesPDL |
|
I |
DEC / 13 |
MetoclopramidePDL |
|
I |
DEC / 13 |
Metolazone or its saltsPDL |
|
I |
DEC / 13 |
Metomidate or its saltsPDL |
|
I |
DEC / 13 |
Metopimazine or its saltsPDL |
|
I |
DEC / 13 |
Metoprolol or its saltsPDL |
|
I |
DEC / 13 |
MetronidazolePDL |
|
I |
DEC / 13 |
Metyrapone or its saltsPDL |
|
I |
DEC / 13 |
Mexiletine or its saltsPDL |
|
I |
DEC / 13 |
Mezlocillin or its salts or derivativesPDL |
For veterinary use
|
I |
DEC / 13 |
Micafungin or its saltsPDL |
|
I |
DEC / 13 |
Miconazole and its salts. |
for vaginal use |
III |
SEP / 98 |
Miconazole and its salts.. |
for topical use |
U |
|
Miconazole or its saltsPDL |
For veterinary use.
|
I |
DEC / 13 |
Miconazole or its saltsPDL |
For human use - except in preparations for topical or vaginal.
|
I |
DEC / 13 |
Midodrine or its saltsPDL |
|
I |
DEC / 13 |
Midostaurin or its saltsPDL |
|
I |
SEP / 17 |
Mifepristone or its derivativesPDL |
|
I |
AUG / 15 |
Migalastat or its saltsPDL |
|
I |
DEC / 17 |
MiglustatPDL |
|
I |
DEC / 13 |
Milbemycin or its derivativesPDL |
For veterinary use - including but not limited to Moxidectin. Moxidectin when sold for the prevention of heartworm in dogs.
|
I |
DEC / 13 |
Milbemycin or its derivativesPDL |
For human use - including but not limited to moxidectin.
|
I |
DEC / 13 |
Milrinone or its saltsPDL |
|
I |
DEC / 13 |
Mineral tar |
except shampoos with concentrations less than 5% |
III |
SEP / 98 |
MinoxidilPDL |
except when sold in preparations for topical use in concentrations of 5% or less, for human use only
|
I |
AUG / 14 |
MinoxidilPDL |
For veterinary use
|
I |
DEC / 13 |
Minoxidil. |
when sold in preparations for topical use in adults in concentrations of 5% or less, for human use only
|
U |
JUL / 17 |
Mirabegron or its saltsPDL |
|
I |
DEC / 13 |
Mirtazapine or its saltsPDL |
|
I |
DEC / 13 |
Mitomycin or its saltsPDL |
|
I |
DEC / 13 |
MitotanePDL |
|
I |
DEC / 13 |
Mitoxantrone or its saltsPDL |
|
I |
DEC / 13 |
MitratapidePDL |
|
I |
FEB / 14 |
Mivacurium chloridePDL |
|
I |
DEC / 13 |
Moclobemide or its salts or derivativesPDL |
|
I |
DEC / 13 |
Modafinil or its saltsPDL |
|
I |
DEC / 13 |
MolgramostimPDL |
|
I |
DEC / 13 |
Mometasone furoateNR |
For the treatment of allergic rhinitis in a nasal spray that delivers 50 mcg/spray for those 12 years of age and older.
|
I |
AUG / 15 |
Monobenzone |
|
II |
SEP / 98 |
Monoethanolamine oleate |
|
II |
SEP / 98 |
Montelukast or its saltsPDL |
|
I |
DEC / 13 |
Moramides, their intermediates, salts, derivatives and salts of intermediates and derivativesN |
Including: Dextromoramide, Diphenylmorpholinoisovaleric acid, Levomoramide, Racemoramide
|
I |
JUN / 02 |
Morphinans, their salts, derivatives and salts of derivativesN |
Including: Buprenorphine, Drotebanol, Levomethorphan, Levorphanol, Levophenacylmorphan, Norlevorphanol, Phenomorphan, Racemethorphan, Racemorphan; but not including: Dextromethorphan and its salts, Dextrorphan and its salts, Levallorphan and its salts, Levargorphan and its salts, Butorphanol and its salts, Nalbuphine and its salts
|
I |
JUN / 02 |
Moxifloxacin or its salts or derivativesPDL |
|
I |
DEC / 13 |
Mumps vaccine |
|
II |
DEC / 98 |
Mupirocin |
|
I |
SEP / 99 |
Muromonab-CD3PDL |
|
I |
DEC / 13 |
Mycophenolic acid or its salts or derivativesPDL |
Including but not limited to Mycophenolate mofetil.
|
I |
DEC / 13 |
NabumetonePDL |
|
I |
DEC / 13 |
Nadolol or its saltsPDL |
|
I |
DEC / 13 |
Nadroparin or its saltsPDL |
|
I |
DEC / 13 |
Nafarelin or its salts or derivativesPDL |
Including but not limited to Nafarelin acetate.
|
I |
DEC / 13 |
Nafcillin or its salts or derivativesPDL |
For veterinary use
|
I |
DEC / 13 |
Nalbuphine and any salt thereofC |
|
I |
JUN / 02 |
Nalidixic acidPDL |
|
I |
DEC / 13 |
Nalmefene or its saltsPDL |
|
I |
DEC / 13 |
Naloxegol or its saltsPDL |
including but not limited to naloxegol oxalate
|
I |
JUN / 15 |
Naloxone hydrochloride injection, |
when indicated for emergency use for opioid overdose
Note: Pharmacists should verify whether there is any additional guidance in their jurisdiction regarding the provision of this drug.
|
II |
FEB / 17 |
Naloxone hydrochloride nasal spray, |
when indicated for emergency use for opioid overdose
Note: Pharmacists should verify whether there is any additional guidance in their jurisdiction regarding the provision of this drug.
|
II |
FEB / 17 |
Naloxone or its saltsPDL |
including, but not limited to naloxone hydrochloride, except when indicated for emergency use for opioid overdose
|
I |
FEB / 17 |
Naltrexone or its salts PDL |
|
I |
DEC / 13 |
Naphazoline and its salts |
in nasal preparations for pediatric use |
II |
SEP / 98 |
Naphazoline and its salts. |
in nasal preparations for adult use and in ophthalmic products |
U |
|
Naproxen or its salts |
Except in preparations containing the equivalent of 200 mg of naproxen base* per oral dosage unit when sold in products labelled with a recommended maximum daily dose equivalent to 400 mg of naproxen base).
[*220 mg naproxen sodium approximately equivalent to 200 mg naproxen base]
|
I |
MAR / 15 |
Naproxen or its salts.. |
In preparations containing the equivalent of 200 mg of naproxen base* per oral dosage unit, when sold in products labelled with a recommended maximum daily dose equivalent to 400 mg of naproxen base, and in package sizes exceeding the equivalent of 6,000 mg of naproxen base.
[*220 mg naproxen sodium approximately equivalent to 200 mg naproxen base]
|
III |
MAR / 15 |
Naproxen or its salts.. |
In preparations containing the equivalent of 200 mg of naproxen base* per oral dosage unit, when sold in products labelled with a recommended maximum daily dose equivalent to 400 mg of naproxen base, and in package sizes of the equivalent of 6,000 mg of naproxen base or less.
[*220 mg naproxen sodium approximately equivalent to 200 mg naproxen base]
|
U |
MAR / 15 |
Naratriptan or its saltsPDL |
|
I |
DEC / 13 |
NatalizumabPDL |
|
I |
DEC / 13 |
Nateglinide or its salts or derivativesPDL |
|
I |
DEC / 13 |
Nebivolol or its salts or derivativesPDL |
|
I |
DEC / 13 |
NecitumumabPDL |
|
I |
APR / 17 |
Nedocromil or its saltsPDL |
|
I |
DEC / 13 |
Nefazodone or its saltsPDL |
|
I |
DEC / 13 |
NelarabinePDL |
|
I |
DEC / 13 |
Nelfinavir or its saltsPDL |
|
I |
DEC / 13 |
Neocinchophen or its saltsPDL |
|
I |
DEC / 13 |
Neomycin or its salts or derivativesPDL |
Including but not limited to: Paromomycin sulfate (for veterinary use)
|
I |
DEC / 18 |
Neostigmine saltsPDL |
|
I |
DEC / 13 |
NepafenacPDL |
|
I |
DEC / 13 |
Neratinib or its salts PDL |
|
I |
OCT / 19 |
Nesiritide or its saltsPDL |
|
I |
DEC / 13 |
NetupitantPDL |
|
I |
DEC / 17 |
Nevirapine or its saltsPDL |
|
I |
DEC / 13 |
Nialamide or its saltsPDL |
|
I |
DEC / 13 |
NicarbazinPDL |
For human use
|
I |
DEC / 13 |
Nicardipine or its saltsPDL |
|
I |
DEC / 13 |
Nicotine or its saltsPDL |
For human use - EXCEPT: (a) in natural substances; (b) in the form of a chewing gum containing 4 mg or less of nicotine per dosage unit; (c) in the form of a transdermal patch with a delivery rate of 22 mg or less of nicotine per day; (d) in a form to be administered into the oral cavity by means of a non-active device (one that operates on energy generated by the human body or by gravity) that delivers 4 mg or less of nicotine per dose for buccal absorption; or (e) in the form of a lozenge containing 4 mg or less of nicotine per dosage unit).
|
I |
AUG / 18 |
Nicotine or its saltsPDL |
For veterinary use.
|
I |
DEC / 13 |
Nicotinic acidPDL |
For human use - when sold in: (a) a modified-release oral dosage form that provides 500 milligrams or more per dosage unit or per daily dose; or (b) an immediate-release oral dosage form that provides more than 500 milligrams per dosage unit or per daily dose.
|
I |
DEC / 13 |
NifedipinePDL |
|
I |
DEC / 13 |
Nikethamide |
|
I |
SEP / 98 |
Nilotinib or its saltsPDL |
|
I |
DEC / 13 |
NilutamidePDL |
|
I |
DEC / 13 |
Nimodipine or its saltsPDL |
|
I |
DEC / 13 |
Nintedanib or its saltsPDL |
|
I |
AUG / 15 |
Niraparib or its salts PDL |
|
I |
OCT / 19 |
NirmatrelvirPDL |
|
I |
JAN / 22 |
NitisinonePDL |
|
I |
NOV / 16 |
Nitric oxidePDL |
|
I |
DEC / 13 |
Nitrofurantoin or its saltsPDL |
For human use.
|
I |
DEC / 13 |
Nitroglycerin |
Except for sublingual immediate release dosage forms.
|
I |
SEP / 98 |
Nitroglycerin. |
sublingual immediate release dosage forms |
II |
SEP / 98 |
NitroscanatePDL |
|
I |
DEC / 13 |
NivolumabPDL |
|
I |
JAN / 16 |
Nizatidine and its saltsNR |
When sold in an oral dosage form containing not more than the equivalent of 75 mg of nizatidine.*
|
I |
SEP / 98 |
Nizatidine or its saltsPDL |
Except when sold in an oral dosage form containing not more than the equivalent of 75 mg of nizatidine.
|
I |
DEC / 13 |
Nomifensine or its saltsPDL |
|
I |
DEC / 13 |
Non-live recombinant herpes zoster vaccine |
*Note that this listing does not apply to live herpes zoster vaccines as they have not been specifically reviewed by the NDSAC. Therefore, live herpes zoster vaccines would follow the general vaccine listings.
|
II |
JUL / 21 |
Norepinephrine and its salts (levarterenol, noradrenaline) |
in injectable form
|
II |
SEP / 98 |
NorfloxacinPDL |
|
I |
DEC / 13 |
Nortriptyline or its saltsPDL |
|
I |
DEC / 13 |
Novobiocin or its salts or derivativesPDL |
For human use.
|
I |
DEC / 13 |
NusinersenPDL |
|
I |
AUG / 17 |
Nylidrin or its saltsPDL |
|
I |
DEC / 13 |
Nystatin and its salts and derivatives. |
in topical preparations for use on the skin |
III |
SEP / 98 |
Nystatin or its salts or derivativesPDL |
For human use - except preparations for topical use on the skin.
|
I |
DEC / 13 |
Obeticholic acid or its saltsPDL |
|
I |
MAY / 17 |
ObiltoxaximabPDL |
|
I |
SEP / 20 |
ObinutuzumabPDL |
|
I |
DEC / 14 |
Oclacitinib or its saltsPDL |
including but not limited to Oclacitinib maleate
|
I |
AUG / 14 |
OcrelizumabPDL |
|
I |
SEP / 17 |
OcriplasminPDL |
|
I |
DEC / 13 |
Octatropine methylbromidePDL |
|
I |
DEC / 13 |
OctreotidePDL |
|
I |
DEC / 13 |
OfatumumabPDL |
|
I |
DEC / 13 |
Ofloxacin or its saltsPDL |
Including but not limited to levofloxacin.
|
I |
DEC / 13 |
Olanzapine or its saltsPDL |
|
I |
DEC / 13 |
OlaparibPDL |
|
I |
AUG / 16 |
OlaratumabPDL |
|
I |
MAR / 18 |
Oleandomycin or its salts or derivativesPDL |
For human use.
|
I |
DEC / 13 |
Olmesartan or its salts or derivativesPDL |
Including but not limited to olmesartan medoxmil.
|
I |
DEC / 13 |
Olodaterol or its saltsPDL |
|
I |
DEC / 13 |
Olopatadine or its saltsPDL |
|
I |
DEC / 13 |
Olsalazine or its saltsPDL |
|
I |
DEC / 13 |
OmalizumabPDL |
|
I |
DEC / 13 |
OmbitasvirPDL |
|
I |
MAR / 15 |
Omeprazole or its salts |
For human use - including but not limited to omeprazole, omeprazole magnesium except when sold for the 14-day treatment for frequent heartburn at a daily dose of 20 mg, in package sizes of no more than 280 mg of omeprazole.
|
I |
SEP / 14 |
Omeprazole or its saltsPDL |
For veterinary use - including but not limited to omeprazole, omeprazole magnesium.
|
I |
DEC / 13 |
Omeprazole or its salts. |
when sold for the 14-day treatment for frequent heartburn at a daily dose of 20 mg, in package sizes of no more than 280 mg of omeprazole
|
II |
SEP / 14 |
Onasemnogene abeparvovecPDL |
|
I |
MAY / 21 |
Ondansetron or its saltsPDL |
|
I |
DEC / 13 |
Opium Poppy (Papaver somniferum), its preparations, derivatives, alkaloids and saltsN |
Including: (1) Opium; (2) Codeine; (3) Morphine; (4) Thebaine; and the salts, derivatives and salts of derivatives of the substances set out in subitems (1) to (4), including: Acetorphine; Acetyldihydrocodeine; Benzylmorphine; Codoxime; Desomorphine; Diacetylmorphine (heroin); Dihydrocodeine; Dihydromorphine; Ethylmorphine; Etorphine; Hydrocodone; Hydromorphinol; Hydromorphone; Methyldesorphine; Methyldihydromorphine; Metopon; Morphine-N-oxide; Myrophine; Nalorphine; Nicocodine; Nicomorphine; Norcodeine; Normorphine; Oxycodone; Oxymorphone; Pholcodine; Thebacon; but not including: Apomorphine; Cyprenorphine and its salts; Nalmefene and its salts; Naloxone and its salts; Naltrexone and its salts; Methylnaltrexone and its salts; Naloxegol and its salts; Narcotine and its salts; Papaverine and its salts; Poppy seed
|
I |
JUN / 02 |
Orbifloxacin or its salts or derivativesPDL |
|
I |
DEC / 13 |
Orciprenaline (Metaproterenol) or its saltsPDL |
|
I |
DEC / 13 |
OrlistatPDL |
|
I |
DEC / 13 |
Ormetoprim or its saltsPDL |
|
I |
DEC / 13 |
OrnidazolePDL |
|
I |
DEC / 13 |
Orphenadrine citrate |
|
III |
SEP / 98 |
Orphenadrine hydrochloride |
|
I |
SEP / 98 |
Oseltamivir or its saltsPDL |
|
I |
DEC / 13 |
Osimertinib or its saltsPDL |
|
I |
AUG / 16 |
OspemifenePDL |
|
I |
SEP / 21 |
Oxacillin, or its salts or derivativesPDL |
For veterinary use
|
I |
DEC / 13 |
OxaliplatinPDL |
|
I |
DEC / 13 |
OxanamidePDL |
|
I |
DEC / 13 |
Oxaprozin or its salts or derivativesPDL |
|
I |
DEC / 13 |
OxcarbazepinePDL |
|
I |
DEC / 13 |
Oxethazine |
|
III |
SEP / 98 |
Oxiconazole |
1% for topical use |
U |
SEP / 99 |
Oxolinic acid or its saltsPDL |
|
I |
DEC / 13 |
Oxprenolol or its saltsPDL |
|
I |
DEC / 13 |
Oxybuprocaine and its salts |
for topical use on mucous membranes, except lozenges
|
III |
SEP / 98 |
Oxybuprocaine and its salts |
benoxinate for ophthalmic or parenteral use
|
II |
SEP / 98 |
Oxybutynin or its saltsPDL |
|
I |
DEC / 13 |
Oxymetazoline |
in nasal preparations for adult use and in ophthalmic products |
U |
|
Oxymetazoline and its salts |
in nasal preparations for pediatric use |
II |
SEP / 98 |
Oxyphenbutazone or its saltsPDL |
|
I |
DEC / 13 |
Oxyquinoline |
|
II |
SEP / 98 |
Oxytetracycline or its saltsPDL |
For veterinary use
|
I |
DEC / 18 |
OxytocinPDL |
|
I |
DEC / 13 |
Ozanimod or its saltsPDL |
|
I |
DEC / 20 |
Ozenoxacin or its saltsPDL |
|
I |
JUN / 17 |
Paclitaxel or its derivativesPDL |
|
I |
DEC / 13 |
Palbociclib or its saltsPDL |
|
I |
AUG / 16 |
PaliferminPDL |
|
I |
DEC / 13 |
Paliperidone or its salts or its derivativesPDL |
|
I |
DEC / 13 |
PalivizumabPDL |
|
I |
DEC / 13 |
Palonosetron or its saltsPDL |
including but not limited to palonosetron hydrochloride
|
I |
DEC / 13 |
Palovarotene or its saltsPDL |
|
I |
JAN / 22 |
Pamidronic acid or its saltsPDL |
|
I |
DEC / 13 |
Pancreatic extractsPDL |
when sold in a dosage form that provides more than 20 000 USP units of lipase activity per dosage unit or indicated for the treatment of pancreatic exocrine insufficiency
|
I |
DEC / 13 |
PancreatinPDL |
when sold in a dosage form that provides more than 20 000 USP units of lipase activity per dosage unit or indicated for the treatment of pancreatic exocrine insufficiency
|
I |
DEC / 13 |
PancrelipasePDL |
when sold in a dosage form that provides more than 20 000 USP units of lipase activity per dosage unit or indicated for the treatment of pancreatic exocrine insufficiency
|
I |
DEC / 13 |
Pancuronium or its saltsPDL |
|
I |
DEC / 13 |
PanitumumabPDL |
|
I |
DEC / 13 |
Pantoprazole or its saltsPDL |
|
I |
DEC / 13 |
Papaveretrine or its salts |
|
I |
SEP / 98 |
Papaverine or its salts |
|
I |
SEP / 98 |
ParaldehydePDL |
|
I |
DEC / 13 |
ParamethadionePDL |
|
I |
DEC / 13 |
Pargyline or its saltsPDL |
|
I |
DEC / 13 |
ParicalcitolPDL |
|
I |
DEC / 13 |
Paritaprevir (Veruprevir)PDL |
|
I |
MAR / 15 |
Paroxetine or its saltsPDL |
|
I |
DEC / 13 |
Paroxypropione |
|
II |
SEP / 98 |
Pasireotide or its saltsPDL |
|
I |
DEC / 13 |
Patiromer sorbitex calciumPDL |
|
I |
NOV / 18 |
Patisiran or its saltsPDL |
|
I |
JUL / 19 |
Pazopanib or its saltsPDL |
|
I |
DEC / 13 |
Pegaptanib or its saltsPDL |
|
I |
DEC / 13 |
PegaspargasePDL |
|
I |
APR / 17 |
PegfilgrastimPDL |
|
I |
DEC / 13 |
PegvaliasePDL |
|
I |
JUN / 22 |
PegvisomantPDL |
|
I |
DEC / 13 |
PembrolizumabPDL |
|
I |
JUN / 15 |
Pemetrexed or its saltsPDL |
|
I |
DEC / 13 |
Pemigatinib or its saltsPDL |
|
I |
OCT / 21 |
Pemoline and any salt thereofC |
|
I |
JAN / 03 |
Penciclovir or its saltsPDL |
|
I |
DEC / 13 |
PenicillaminePDL |
|
I |
DEC / 13 |
Penicillin or its salts or derivativesPDL |
Including but not limited to:
Amoxicillin, ampicillin, azlocillin, benzathine penicillin, carbenicillin, cloxacillin, dicloxacillin, hetacillin, mecillinam, methicillin, mezlocillin, nafcillin, oxacillin, ticarcillin, penicillin G (benzyl penicillin), procaine penicillin G.
|
I |
DEC / 18 |
Pentaerythritol tetranitrate |
|
I |
SEP / 98 |
Pentagastrin and its salts |
|
II |
SEP / 98 |
Pentamidine or its saltsPDL |
|
I |
DEC / 13 |
PentobarbitalC |
|
I |
JUN / 02 |
Pentolinium tartratePDL |
|
I |
DEC / 13 |
Pentosan polysulfate or its saltsPDL |
|
I |
DEC / 13 |
Pentostatin or its saltsPDL |
|
I |
DEC / 13 |
Pentoxifylline or its saltsPDL |
|
I |
DEC / 13 |
Peramivir or its salts or derivativesPDL |
|
I |
MAR / 17 |
PerampanelPDL |
|
I |
DEC / 13 |
PerflutrenPDL |
|
I |
DEC / 13 |
Pergolide or its saltsPDL |
|
I |
DEC / 13 |
Pericyazine or its saltsPDL |
|
I |
DEC / 13 |
Perindopril or its saltsPDL |
|
I |
DEC / 13 |
Permethrin and its derivatives |
|
II |
SEP / 98 |
Permethrin or its derivativesPDL |
For veterinary use, when recommended in cats.
|
I |
DEC / 13 |
Perphenazine or its saltsPDL |
|
I |
DEC / 13 |
Pertussis vaccine |
|
II |
DEC / 98 |
PertuzumabPDL |
|
I |
DEC / 13 |
Phacetoperane or its saltsPDL |
|
I |
DEC / 13 |
PhenacemidePDL |
|
I |
DEC / 13 |
PhenacetinPDL |
|
I |
DEC / 13 |
PhenaglycodolPDL |
|
I |
DEC / 13 |
Phenalkoxams, their salts, derivatives and salts of derivativesN |
Including: Dimenoxadol, Dioxaphetyl butyrate, Dextropropoxyphene
|
I |
JUN / 02 |
Phenazepines, their salts, derivatives and salts of derivativesN |
Including: Proheptazine; but not including: Ethoheptazine and its salts; Metethoheptazine and its salts; Metheptazine and its salts
|
I |
JUN / 02 |
Phenazopyridine or its saltsPDL |
|
I |
DEC / 13 |
Phencyclidine, its salts, derivatives and analogues and salts of derivatives and analoguesN |
Including: Ketamine
|
I |
JUN / 02 |
Phendimetrazine and any salt thereofC |
|
I |
JUN / 02 |
Phenelzine or its saltsPDL |
|
I |
DEC / 13 |
Phenformin and its saltsPDL |
|
I |
DEC / 13 |
Pheniprazine or its saltsPDL |
|
I |
DEC / 13 |
Pheniramine |
|
U |
|
Phenmetrazine and any salt thereofC |
|
I |
JUN / 02 |
Phenoxybenzamine and its salts |
|
II |
SEP / 98 |
Phentermine and any salt thereofC |
|
I |
JUN / 02 |
Phenthoxate or its saltsPDL |
|
I |
DEC / 13 |
Phentolamine or its saltsPDL |
|
I |
DEC / 13 |
Phenylbutazone or its saltsPDL |
|
I |
DEC / 13 |
Phenylbutyric acid or its salts or derivativesPDL |
Including but not limited to glycerol phenylbutyrate, phenylbutyrate sodium.
|
I |
AUG / 16 |
Phenylephrine and its salts and preparations |
in nasal preparations in concentrations of 2.5% or less, for pediatric use |
II |
SEP / 98 |
Phenylephrine and its salts and preparations. |
for oral use, in nasal preparations for adults and in ophthalmic preparations in concentrations of 2.5% or less |
U |
|
Phenylephrine or its saltsPDL |
In preparations for parenteral use or ophthalmic use in concentrations greater than 2.5%.
|
I |
DEC / 13 |
Phenylindanedione or its derivativesPDL |
|
I |
DEC / 13 |
Phenylpiperidines, their intermediates, salts, derivatives and analogues and salts of intermediates, derivatives and analoguesN |
Including: Allylprodine; Alphameprodine; Alphaprodine; Anileridine; Betameprodine; Betaprodine; Benzethidine; Diphenoxylate; Difenoxin; Etoxeridine; Furethidine; Hydroxypethidine; Ketobemidone; Methylphenylisonipecotonitrile; Morpheridine; Norpethidine; Pethidine; Phenoperidine; Piminodine; Properidine; Trimeperidine; Pethidine Intermediate C; but not including: Carperidine and its salts; Oxpheneridine and its salts
|
I |
JUN / 02 |
Phenylpropanolamine or its salts or derivativesPDL |
|
I |
DEC / 13 |
Phenyltoloxamine and its salts |
|
III |
SEP / 98 |
Physostigmine salicylatePDL |
For human use - except preparations for oral or topical use only.
|
I |
DEC / 13 |
Phytocannabinoids produced by, or found in, the cannabis plant and substances that are duplicates of such phytocannabinoids.*PDL |
except:
1) derivatives of cannabis as defined in subsection 2(1) of the Cannabis Act that are exempt from the application of the Cannabis Act under the Industrial Hemp Regulations and that do not contain an isolated or concentrated phytocannabinoid or a synthetic duplicate of that phytocannabinoid, or
2) anything referred to in Schedule 2 to the Cannabis Act that contains no more than 10 µg/g delta-9-tetrahydrocannabinol and that does not contain an isolated or concentrated phytocannabinoid or a synthetic duplicate of that phytocannabinoid.
*Note: this listing is copied from the Health Canada Prescription Drug List and applies to products that have received a Notice of Compliance and Drug Identification Number and been classified as prescription drugs by Health Canada. Cannabis products, as defined in the Cannabis Act and its regulations, are not granted a Notice of Compliance and Drug Identification Number by Health Canada and are considered outside the scope of the National Drug Schedules.
|
I |
OCT / 18 |
PibrentasvirPDL |
|
I |
SEP / 17 |
Pilocarpine or its saltsPDL |
|
I |
DEC / 13 |
PimecrolimusPDL |
|
I |
DEC / 13 |
PimobendanPDL |
|
I |
DEC / 13 |
PimozidePDL |
|
I |
DEC / 13 |
Pinaverium bromidePDL |
|
I |
DEC / 13 |
Pindolol or its saltsPDL |
|
I |
DEC / 13 |
Pioglitazone or its saltsPDL |
|
I |
DEC / 13 |
Pipecuronium bromidePDL |
|
I |
DEC / 13 |
Piperacetazine or its saltsPDL |
|
I |
DEC / 13 |
Piperazine and its salts |
|
II |
SEP / 98 |
Piperilate or its saltsPDL |
|
I |
DEC / 13 |
Piperonyl butoxide |
|
II |
SEP / 98 |
PipobromanPDL |
|
I |
DEC / 13 |
Pipotiazine or its saltsPDL |
|
I |
DEC / 13 |
Pipradrol and any salt thereofTS |
|
I |
SEP / 98 |
Pirbuterol or its saltsPDL |
|
I |
DEC / 13 |
Pirenzepine or its saltsPDL |
|
I |
DEC / 13 |
Pirfenidone or its derivativesPDL |
|
I |
DEC / 13 |
Pirlimycin or its saltsPDL |
|
I |
DEC / 13 |
Piroxicam or its saltsPDL |
|
I |
DEC / 13 |
Pitolisant or its saltsPDL |
|
I |
JUL / 21 |
Pizotyline or its saltsPDL |
|
I |
DEC / 13 |
Plecanatide PDL |
|
I |
NOV / 19 |
Plerixafor or its saltsPDL |
|
I |
DEC / 13 |
Pneumococcal 7-valent conjugate vaccine |
|
II |
JAN / 04 |
Pneumococcal polysaccharide vaccines |
|
II |
FEB / 02 |
PodophyllotoxinPDL |
When recommended for topical use.
|
I |
DEC / 13 |
Polatuzumab vedotin PDL |
|
I |
SEP / 20 |
PolidocanolPDL |
When indicated for administration by injection.
|
I |
JAN / 16 |
Poliomyelitis vaccine |
|
II |
DEC / 98 |
Polyacrylamide |
|
II |
SEP / 98 |
Polyethylene glycol |
topical administration |
U |
|
Polyethylene glycol 3350 |
as a single ingredient oral product indicated as a laxative to treat occasional constipation |
U |
JUL / 10 |
Polymyxin B or its salts or derivativesPDL |
For human use - except for topical use or for local action in the oral cavity or nasal passages.
|
I |
DEC / 13 |
Polymyxin B or its salts or derivatives.PDL |
For veterinary use - when sold in combination with other medicinal ingredients.
|
I |
APR / 16 |
Polymyxin B or its salts or derivatives.. |
for human, ophthalmic use
|
III |
JUN / 06 |
Polymyxin or its salts or derivatives |
for human, topical use |
U |
|
Polysulfated glycosaminoglycanPDL |
|
I |
DEC / 13 |
Pomalidomide or its saltsPDL |
|
I |
FEB / 14 |
Ponatinib or its saltsPDL |
|
I |
MAY / 15 |
PonesimodPDL |
|
I |
MAY / 21 |
Poractant alfaPDL |
|
I |
DEC / 13 |
Porfimer or its saltsPDL |
|
I |
DEC / 13 |
PosaconazolePDL |
|
I |
DEC / 13 |
Potassium bromidePDL |
|
I |
DEC / 13 |
Potassium citratePDL |
When recommended for the treatment of renal tubular acidosis and kidney stones.
|
I |
DEC / 13 |
Potassium gluconatePDL |
For veterinary use - when sold or recommended for administration to cats.
|
I |
DEC / 13 |
Potassium para-aminobenzoatePDL |
Except in preparations for topical use on the skin.
|
I |
DEC / 13 |
Potassium salts |
In preparations for injection.
|
I |
DEC / 99 |
Pradofloxacin or their salts or derivativesPDL |
|
I |
MAR / 15 |
Pralatrexate or its saltsPDL |
|
I |
DEC / 18 |
Pralidoxime or its saltsPDL |
|
I |
DEC / 13 |
Pralsetinib or its saltsPDL |
|
I |
SEP / 21 |
Pramipexole or its saltsPDL |
|
I |
DEC / 13 |
Pramoxine and its salts |
for ophthalmic or parenteral use |
II |
SEP / 98 |
Pramoxine and its salts. |
for topical use on mucous membranes, except lozenges
|
III |
SEP / 98 |
Pramoxine and its salts.. |
for topical application on the skin, and including lozenges |
U |
DEC / 05 |
Prasugrel or its saltsPDL |
|
I |
DEC / 13 |
Pravastatin or its saltsPDL |
|
I |
DEC / 13 |
PraziquantelPDL |
For human use.
|
I |
DEC / 13 |
PraziquantelPDL |
For veterinary use - except when sold for the treatment of the tapeworm Anoplocephala perfoliata in horses.
|
I |
DEC / 13 |
Prazosin or its saltsPDL |
|
I |
DEC / 13 |
Pregabalin or its salts or derivativesPDL |
|
I |
DEC / 13 |
Prenylamine or its saltsPDL |
|
I |
DEC / 13 |
Prilocaine and its salts |
for ophthalmic or parenteral use
|
II |
SEP / 98 |
Prilocaine and its salts. |
for topical use on mucous membranes, except lozenges
|
III |
SEP / 98 |
Primaquine or its saltsPDL |
|
I |
DEC / 13 |
PrimidonePDL |
For human use.
|
I |
DEC / 13 |
Probenecid or its saltsPDL |
|
I |
DEC / 13 |
ProbucolPDL |
|
I |
DEC / 13 |
Procainamide or its saltsPDL |
|
I |
DEC / 13 |
Procaine and its salts |
for topical use on mucous membranes, except lozenges |
III |
SEP / 98 |
Procaine and its salts |
for ophthalmic or parenteral use |
II |
SEP / 98 |
Procarbazine or its saltsPDL |
|
I |
DEC / 13 |
Procaterol or its saltsPDL |
|
I |
DEC / 13 |
Prochlorperazine or its saltsPDL |
|
I |
DEC / 13 |
Procyclidine or its saltsPDL |
|
I |
DEC / 13 |
Prodilidine or its saltsPDL |
|
I |
DEC / 13 |
Profenamine or its saltsPDL |
Including but not limited to ethopropazine.
|
I |
DEC / 13 |
Progesterone or its derivativesPDL |
For veterinary use - except when recommended for use in progesterone implants indicated for growth promotion, melengestrol acetate in feed for the suppression of estrus in beef heifers.
|
I |
DEC / 13 |
Proguanil or its saltsPDL |
|
I |
DEC / 13 |
Promazine or its saltsPDL |
For human use.
|
I |
DEC / 13 |
Promethazine and its salts |
for topical use |
III |
SEP / 98 |
Promethazine and its salts |
except for topical use |
II |
SEP / 98 |
Propafenone or its saltsPDL |
|
I |
DEC / 13 |
Propantheline and its salts |
|
II |
SEP / 98 |
Proparacaine and its salts |
for ophthalmic or parenteral use |
II |
SEP / 98 |
Proparacaine and its salts |
for topical use on mucous membranes, except lozenges |
III |
SEP / 98 |
Propiverine or its saltsPDL |
|
I |
MAR / 17 |
PropofolPDL |
|
I |
DEC / 13 |
Propranolol or its saltsPDL |
|
I |
DEC / 13 |
Propylene glycol |
topical application |
U |
|
Propylhexedrine |
|
II |
SEP / 98 |
Propylthiouracil or its salts PDL |
|
I |
OCT / 21 |
Proquamezine [aminopromazine] and its salts |
For internal use.
|
I |
SEP / 98 |
Prostaglandins or their salts or derivatives or analoguesPDL |
Including but not limited to: Alprostadil, bimatoprost, cloprostenol, dinoprostone, epoprostenol, fluprostenol, latanoprost, latanoprostene bunod, lubiprostone, misoprostol, tafluprost, travoprost, treprostinil, unoprostone.
|
I |
AUG / 15 |
Protamine and its salts |
|
II |
SEP / 98 |
Prothipendyl hydrochloridePDL |
|
I |
DEC / 13 |
ProtirelinPDL |
|
I |
DEC / 13 |
Protriptyline or its saltsPDL |
|
I |
DEC / 13 |
Prucalopride or its saltsPDL |
Including but not limited to prucalopride succinate.
|
I |
DEC / 13 |
Pseudoephedrine and its salts and preparations in combination products |
Note: Pharmacists are advised that in areas where there is evidence of abuse or particular concern about abuse, pseudoephedrine products should not be located in a self-selection area of the pharmacy |
III |
APR / 06 |
Pseudoephedrine and its salts and preparations in single entity products |
|
II |
APR / 06 |
Pyrantel and its salts |
|
II |
SEP / 98 |
PyrazinamidePDL |
|
I |
DEC / 13 |
Pyridostigmine bromidePDL |
|
I |
DEC / 13 |
Pyrilamine |
|
U |
|
Pyrimethamine or its saltsPDL |
|
I |
DEC / 13 |
Pyrovalerone and any salt thereofC |
|
I |
JAN / 03 |
Pyrvinium and its salts |
|
II |
SEP / 98 |
Quetiapine or its saltsPDL |
|
I |
DEC / 13 |
Quinagolide or its saltsPDL |
|
I |
DEC / 13 |
Quinapril or its salts or derivativesPDL |
|
I |
DEC / 13 |
Quinine or its salts or derivativesPDL |
Except when sold in oral dosage form that provides 50 mg or less of quinine base per dosage unit or per daily dose.
|
I |
DEC / 13 |
Quinupristin or its saltsPDL |
|
I |
DEC / 13 |
Rabeprazole or its saltsPDL |
|
I |
DEC / 13 |
Rabies immune globulin |
|
I |
FEB / 02 |
Rabies vaccine |
|
I |
FEB / 02 |
Raloxifene or its saltsPDL |
|
I |
DEC / 13 |
Raltegravir or its saltsPDL |
|
I |
DEC / 13 |
Raltitrexed or its salts or derivativesPDL |
Including but not limited to raltitrexed disodium.
|
I |
DEC / 13 |
Ramipril or its salts or derivativesPDL |
|
I |
DEC / 13 |
RamucirumabPDL |
|
I |
OCT / 15 |
RanibizumabPDL |
|
I |
DEC / 13 |
Ranitidine or its saltsPDL |
For human use - except when sold in concentrations of 150 mg or less per oral dosage unit and indicated for the treatment of heartburn.
|
I |
DEC / 13 |
Ranitidine or its salts. |
when sold in concentrations of 150 mg or less per oral dosage unit and indicated for the treatment of heartburn, in package sizes containing more than 4,500 mg of ranitidine |
III |
MAR / 08 |
Ranitidine or its salts.. |
when sold in concentrations of 150 mg or less per oral dosage unit and indicated for the treatment of heartburn, in package sizes containing no more than 4,500 mg of ranitidine |
U |
FEB / 07 |
Ranolazine or its saltsPDL |
|
I |
MAY / 21 |
Rasagiline or its saltsPDL |
|
I |
DEC / 13 |
RasburicasePDL |
|
I |
DEC / 13 |
Raubasine or its saltsPDL |
|
I |
DEC / 13 |
RauwolfiaPDL |
|
I |
DEC / 13 |
RavulizumabPDL |
|
I |
OCT / 19 |
Regorafenib or its saltsPDL |
|
I |
DEC / 13 |
Remdesivir or its salts or derivativesPDL |
|
I |
JUL / 20 |
Remestemcel-LPDL |
|
I |
DEC / 13 |
Remoxipride or its saltsPDL |
|
I |
DEC / 13 |
Repaglinide or its salts or derivativesPDL |
|
I |
DEC / 13 |
Rescinnamine or its saltsPDL |
|
I |
DEC / 13 |
Reserpine or its saltsPDL |
For human use.
|
I |
DEC / 13 |
ReslizumabPDL |
|
I |
JUN / 17 |
Resocortol or its derivativesPDL |
|
I |
DEC / 13 |
RetapamulinPDL |
|
I |
DEC / 13 |
Reviparin or its saltsPDL |
|
I |
DEC / 13 |
Rho D immune globulin |
|
I |
FEB / 02 |
RibavirinPDL |
|
I |
DEC / 13 |
Ribociclib or its saltsPDL |
|
I |
MAY / 18 |
Rifabutin or its saltsPDL |
|
I |
DEC / 13 |
Rifampin or its salts or derivativesPDL |
|
I |
DEC / 13 |
Rifaximin or its salts or derivativesPDL |
|
I |
DEC / 13 |
Rilpivirine or its salts or derivativesPDL |
Including but not limited to rilpivirine hydrochloride.
|
I |
DEC / 13 |
Riluzole or its saltsPDL |
|
I |
DEC / 13 |
Riociguat or its derivativesPDL |
|
I |
DEC / 13 |
Ripretinib or its salts PDL |
|
I |
SEP / 20 |
RisankizumabPDL |
|
I |
JUL / 19 |
Risdiplam or its salts or derivativesPDL |
|
I |
JUL / 21 |
Risedronic acid or its saltsPDL |
|
I |
DEC / 13 |
Risperidone or its saltsPDL |
|
I |
DEC / 13 |
Ritodrine or its saltsPDL |
|
I |
DEC / 13 |
RitonavirPDL |
|
I |
DEC / 13 |
RituximabPDL |
|
I |
DEC / 13 |
RivaroxabanPDL |
|
I |
DEC / 13 |
Rivastigmine or its saltsPDL |
|
I |
DEC / 13 |
Rizatriptan or its saltsPDL |
|
I |
DEC / 13 |
Robenacoxib or its saltsPDL |
|
I |
DEC / 13 |
Rocuronium bromidePDL |
|
I |
DEC / 13 |
RofecoxibPDL |
|
I |
DEC / 13 |
Roflumilast or its salts or derivativesPDL |
|
I |
DEC / 13 |
RomidepsinPDL |
|
I |
DEC / 13 |
Romifidine or its saltsPDL |
|
I |
DEC / 13 |
RomiplostimPDL |
|
I |
DEC / 13 |
Romosozumab PDL |
|
I |
OCT / 19 |
Ronidazole or its salts or derivativesPDL |
For human use.
|
I |
DEC / 13 |
Ropinirole or its saltsPDL |
|
I |
DEC / 13 |
Rose Bengal |
|
II |
SEP / 98 |
Rosiglitazone or its saltsPDL |
|
I |
DEC / 13 |
Rosoxacin or its saltsPDL |
|
I |
DEC / 13 |
Rosuvastatin or its saltsPDL |
|
I |
DEC / 13 |
Rotigotine or its salts or derivativesPDL |
|
I |
DEC / 13 |
Rubella vaccine |
|
II |
DEC / 98 |
Rufinamide or its derivativesPDL |
|
I |
DEC / 13 |
Rupatadine or its saltsPDL |
|
I |
FEB / 17 |
Ruxolitinib or its saltsPDL |
Including but not limited to ruxolitinib phosphate.
|
I |
DEC / 13 |
Sacituzumab govitecanPDL |
|
I |
OCT / 21 |
Sacubitril or its saltsPDL |
|
I |
JAN / 16 |
Safinamide or its saltsPDL |
|
I |
FEB / 19 |
Salbutamol or its saltsPDL |
|
I |
DEC / 13 |
Salicylic acidPDL |
When sold in topical formulations containing salicylic acid at concentrations greater than 20% and/or with a pH less than 3.0, except when sold to be applied to warts, corns or calluses.
|
I |
DEC / 14 |
Salmeterol or its saltsPDL |
|
I |
DEC / 13 |
Salsalate or its salts or derivativesPDL |
|
I |
DEC / 13 |
Sapropterin or its saltsPDL |
|
I |
DEC / 13 |
Saquinavir or its salts or derivativesPDL |
|
I |
DEC / 13 |
Saralasin or its saltsPDL |
|
I |
DEC / 13 |
SargramostimPDL |
|
I |
DEC / 13 |
SarilumabPDL |
|
I |
MAR / 17 |
SarolanerPDL |
For veterinary use.
|
I |
AUG / 16 |
Satralizumab PDL |
|
I |
SEP / 20 |
Saxagliptin or its saltsPDL |
|
I |
DEC / 13 |
Sebelipase alfaPDL |
|
I |
MAR / 18 |
SecobarbitalC |
|
I |
JUN / 02 |
SecukinumabPDL |
|
I |
MAY / 15 |
Selegiline or its saltsPDL |
|
I |
DEC / 13 |
Selenium in injectable form for parenteral nutrition |
|
I |
JAN / 03 |
Selexipag or its derivativesPDL |
|
I |
AUG / 16 |
Selpercatinib or its saltsPDL |
|
I |
JUL / 21 |
SemaglutidePDL |
|
I |
MAR / 18 |
Sermorelin or its saltsPDL |
|
I |
DEC / 13 |
Sertraline or its saltsPDL |
|
I |
DEC / 13 |
Sevelamer or its saltsPDL |
|
I |
DEC / 13 |
SevofluranePDL |
|
I |
DEC / 13 |
Sex hormones (natural or synthetic)PDL |
For human use - including but not limited to conjugated estrogens, desogestrel, dienogest, estradiol benzoate, estradiol(hemihydrate), estrone, ethinyl estradiol, ethynodiol diacetate, etonogestrel, levonorgestrel, medroxyprogesterone acetate, norelgestromin, norethindrone acetate, norgestimate, progesterone except the following: androisoxazole, androstanolone, androstenediol or its derivatives, bolandiol or its derivatives, bolasterone, bolazine, boldenone or its derivatives, bolenol, calusterone, clostebol or its derivatives, drostanolone or its derivatives, enestebol, epitiostanol, ethylestrenol, fluoxymesterone, formebolone, furazabol, 4-Hydroxy-19-nortestosterone or its derivatives, levonorgestrel when sold as a single ingredient in an oral dosage form containing no more than 1.5 milligrams, mebolazine,mesabolone, mesterolone, metandienone, metenolone or its derivatives, methandriol, methyltestosterone or its derivatives, metribolone, mibolerone, nandrolone or its derivatives, norboletone, norclostebol or its derivatives, norethandrolone, oxabolone or its derivatives, oxandrolone, oxymesterone, oxymetholone, prasterone, quinbolone, stanozolol, stenbolone or its derivatives, testosterone or its derivatives, tibolone, tiomesterone, trenbolone or its derivatives, zeranol.
|
I |
AUG / 15 |
Sibutramine or its saltsPDL |
|
I |
DEC / 13 |
Sildenafil or its saltsPDL |
|
I |
DEC / 13 |
Silodosin or its salts or derivativesPDL |
|
I |
DEC / 13 |
SiltuximabPDL |
|
I |
DEC / 14 |
Simeprevir or its saltsPDL |
|
I |
DEC / 13 |
SimvastatinPDL |
|
I |
DEC / 13 |
Sincalide |
|
II |
SEP / 98 |
Siponimod or its saltsPDL |
|
I |
JUL / 20 |
Sirolimus or its derivativesPDL |
Including but not limited to everolimus, temsirolimus.
|
I |
DEC / 13 |
Sitagliptin or its saltsPDL |
|
I |
DEC / 13 |
Sitaxentan or its saltsPDL |
|
I |
DEC / 13 |
Sodium acetate |
in injectable form
|
II |
SEP / 98 |
Sodium acetate in injectable form for parenteral nutrition |
|
I |
JAN / 03 |
Sodium biphosphate |
in injectable form
|
II |
SEP / 98 |
Sodium bromidePDL |
|
I |
DEC / 13 |
Sodium chloride |
single ingredient solutions for injectable use in concentrations of more than 0.9%
|
II |
OCT / 98 |
Sodium chloride in injectable form for parenteral nutrition |
|
I |
JAN / 03 |
Sodium citrate |
in injectable form
|
II |
SEP / 98 |
Sodium cromoglicate (cromoglycate) |
in solutions in concentrations of 2% or less for ophthalmic or nasal use |
III |
SEP / 98 |
Sodium fluoride (see Fluoride)PDL |
For human use - in solid oral dosage forms containing more than 1 mg of fluoride ion.
|
I |
DEC / 13 |
Sodium iodide |
in injectable form, when used as a sclerosing agent
|
II |
SEP / 98 |
Sodium iodine in injectable form for parenteral nutrition |
|
I |
JAN / 03 |
Sodium nitritePDL |
When indicated for administration by injection and sequential use with sodium thiosulfate for the treatment of acute cyanide poisoning.
|
I |
JUN / 15 |
Sodium nitroprusside or its saltsPDL |
|
I |
DEC / 13 |
Sodium phosphate |
in injectable form
|
II |
SEP / 98 |
Sodium phosphate in injectable form for parenteral nutrition |
|
I |
JAN / 03 |
Sodium picosulphate |
for oral purgatives, 10 mg per pack (when found in preparations with magnesium oxide 3.5 g and citric acid 12 g)
|
II |
JAN / 10 |
Sodium polystyrene sulfonatePDL |
|
I |
DEC / 13 |
Sodium tetradecylsulfate |
|
II |
SEP / 98 |
Sodium zirconium cyclosilicatePDL |
|
I |
OCT / 19 |
Sofosbuvir or its saltsPDL |
|
I |
FEB / 14 |
Solifenacin or its saltsPDL |
|
I |
DEC / 13 |
Solriamfetol or its saltsPDL |
|
I |
JUL / 21 |
SomatostatinPDL |
|
I |
DEC / 13 |
SomatremPDL |
|
I |
DEC / 13 |
SomatrogonPDL |
|
I |
NOV / 21 |
SomatropinPDL |
|
I |
DEC / 13 |
Sonidegib or its salts PDL |
|
I |
SEP / 20 |
Sorafenib or its saltsPDL |
|
I |
DEC / 13 |
Sotalol or its saltsPDL |
|
I |
DEC / 13 |
SotorasibPDL |
|
I |
OCT / 21 |
SotrovimabPDL |
|
I |
AUG / 21 |
Spectinomycin or its salts or derivativesPDL |
|
I |
DEC / 18 |
Spinosyn A and D isoformsPDL |
|
I |
DEC / 13 |
Spiramycin or its salts or derivativesPDL |
For human use.
|
I |
DEC / 13 |
SpironolactonePDL |
|
I |
DEC / 13 |
StavudinePDL |
|
I |
DEC / 13 |
StiripentolPDL |
|
I |
DEC / 13 |
Streptokinase |
as a debriding agent |
II |
SEP / 98 |
Streptokinase/streptodornase |
|
I |
SEP / 98 |
Streptomycin or its salts or derivativesPDL |
For human use
|
I |
DEC / 18 |
Streptomycin or its salts or derivativesPDL |
For veterinary use, including but not limited to dihydrostreptomycin
|
I |
DEC / 18 |
StreptozocinPDL |
|
I |
DEC / 13 |
Strontium and its salts |
in injectable form (except strontium bromide)
|
II |
SEP / 98 |
Strontium bromidePDL |
|
I |
DEC / 13 |
Succinimide or its salts or derivativesPDL |
Including but not limited to methsuximide, except those compounds used for decontaminating water.
|
I |
DEC / 13 |
Succinylcholine and its salts |
|
I |
SEP / 98 |
SucralfatePDL |
|
I |
DEC / 13 |
Sucroferric oxyhydroxidePDL |
|
I |
MAY / 18 |
Sugammadex or its saltsPDL |
|
I |
AUG / 16 |
Sulconazole or its saltsPDL |
|
I |
DEC / 13 |
Sulfinpyrazone or its saltsPDL |
|
I |
DEC / 13 |
Sulindac or its saltsPDL |
|
I |
DEC / 13 |
Sulphonamides or their salts or derivativesPDL |
Including but not limited to Brinzolamide, succinylsulfathiazole, sulfacetamide, sulfadiazine, sulfadimethoxine, sulfadoxine, sulfaguanidine, sulfamerazine, sulfamethazine, sulfamethoxazole, sulfanilamide, sulfapyridine, sulfaquinoxaline, sulfasalazine, sulfathiazole, sulfisoxazole, sulphanilamide
|
I |
DEC / 18 |
Sulphones or their derivativesPDL |
Including but not limited to dapsone.
|
I |
DEC / 13 |
Sumatriptan or its saltsPDL |
|
I |
DEC / 13 |
Sunitinib or its saltsPDL |
|
I |
DEC / 13 |
Suprofen or its saltsPDL |
|
I |
DEC / 13 |
Sutilains |
|
II |
SEP / 98 |
SuvorexantPDL |
|
I |
DEC / 18 |
Suxamethonium chloridePDL |
|
I |
DEC / 13 |
Synthetic cannabinoid receptor type-1 agonists, their salts, derivatives, isomers, and salts of derivatives and isomers N |
as listed in the schedule to the Narcotic Control Regulations under the Controlled Drugs and Substances Act
(Note: includes nabilone)
|
I |
JUL / 15 |
Tacrolimus or its derivativesPDL |
|
I |
DEC / 13 |
Tadalafil or its saltsPDL |
|
I |
DEC / 13 |
Tafamidis or its saltsPDL |
|
I |
FEB / 20 |
TafasitamabPDL |
|
I |
SEP / 21 |
Talazoparib or its salts PDL |
|
I |
NOV / 19 |
Taliglucerase alfaPDL |
|
I |
JUN / 14 |
Tamoxifen or its saltsPDL |
|
I |
DEC / 13 |
Tamsulosin or its saltsPDL |
|
I |
DEC / 13 |
Tapentadol, its salts, derivatives and isomers and salts of derivatives and isomersN |
|
I |
JAN / 16 |
TazarotenePDL |
|
I |
DEC / 13 |
Tazobactam or its salts or derivativesPDL |
|
I |
DEC / 13 |
TecovirimatPDL |
|
I |
JAN / 22 |
Tedizolid or its salts or derivativesPDL |
Including but not limited to Tedizolid phosphate.
|
I |
MAY / 15 |
TeduglutidePDL |
|
I |
OCT / 15 |
TeflubenzuronPDL |
|
I |
DEC / 13 |
Tegaserod or its saltsPDL |
|
I |
DEC / 13 |
Telaprevir or its derivativesPDL |
|
I |
DEC / 13 |
TelbivudinePDL |
|
I |
DEC / 13 |
Telmisartan or its salts or derivativesPDL |
|
I |
DEC / 13 |
Telotristat or its salts or derivativesPDL |
|
I |
NOV / 18 |
Temozolomide or its saltsPDL |
|
I |
DEC / 13 |
Tenapanor or its saltsPDL |
|
I |
JUL / 20 |
TeniposidePDL |
|
I |
DEC / 13 |
Tenofovir or its salts or derivativesPDL |
Including but not limited to: tenofovir disoproxil, tenofovir alafenamide
|
I |
DEC / 13 |
Tenoxicam or its saltsPDL |
|
I |
DEC / 13 |
Tepotinib or its saltsPDL |
|
I |
JUL / 21 |
Tepoxalin or its derivativesPDL |
|
I |
DEC / 13 |
Terazosin or its saltsPDL |
|
I |
DEC / 13 |
Terbinafine or its saltsPDL |
|
I |
DEC / 13 |
Terbutaline or its saltsPDL |
|
I |
DEC / 13 |
Terconazole or its saltsPDL |
|
I |
DEC / 13 |
Terfenadine or its saltsPDL |
|
I |
DEC / 13 |
Teriparatide or its saltsPDL |
|
I |
DEC / 13 |
Terlipressin or its saltsPDL |
|
I |
DEC / 13 |
Tesamorelin or its salts or derivativesPDL |
|
I |
APR / 14 |
Tetanus immune globulin |
|
I |
FEB / 02 |
Tetanus toxoid |
|
II |
DEC / 98 |
Tetrabenazine or its saltsPDL |
|
I |
DEC / 13 |
TetracainePDL |
when in a preparation containing an equal amount of lidocaine and recommended for topical use on the skin, in concentrations of 7% or higher
|
I |
FEB / 14 |
Tetracaine and its salts |
for topical use on mucous membranes, except lozenges |
III |
SEP / 98 |
Tetracaine and its salts |
for ophthalmic or parenteral use
|
II |
SEP / 98 |
Tetracosactide or its saltsPDL |
For veterinary use
|
I |
JUL / 20 |
Tetracycline or its salts or derivativesPDL |
|
I |
DEC / 18 |
Tetrahydrozoline |
in nasal preparations for pediatric use |
II |
SEP / 98 |
Tetrahydrozoline. |
for ophthalmic use and in nasal preparations for adults |
U |
|
Tezacaftor or its saltsPDL |
|
I |
JUL / 18 |
ThalidomidePDL |
|
I |
DEC / 13 |
Theophylline or its saltsPDL |
|
I |
DEC / 13 |
ThiabendazolePDL |
For human use
|
I |
DEC / 13 |
Thiambutenes, their salts, derivatives and salts of derivativesN |
Including: Diethylthiambutene, Dimethylthiambutene, Ethylmethylthiambutene
|
I |
JUN / 02 |
Thiethylperazine or its saltsPDL |
|
I |
DEC / 13 |
Thiobarbiturates, their salts and derivativesC |
Including: Thialbarbital; Thiamylal; Thiobarbituric Acid; Thiopental
|
I |
JUN / 02 |
ThiocarlidePDL |
|
I |
DEC / 13 |
ThioguaninePDL |
|
I |
DEC / 13 |
Thiopropazate or its saltsPDL |
|
I |
DEC / 13 |
Thioproperazine or its saltsPDL |
|
I |
DEC / 13 |
Thioridazine or its saltsPDL |
|
I |
DEC / 13 |
ThiotepaPDL |
|
I |
DEC / 13 |
Thiothixene or its saltsPDL |
|
I |
DEC / 13 |
Thiouracil or its derivativesPDL |
|
I |
DEC / 13 |
Thrombin |
|
II |
SEP / 98 |
Thyroglobulin |
|
II |
SEP / 98 |
ThyroidPDL |
For human use
|
I |
DEC / 13 |
Thyrotropin |
|
II |
SEP / 98 |
Thyrotropin alfaPDL |
|
I |
DEC / 13 |
Thyroxin or its saltsPDL |
Including but not limited to Levothyroxine sodium
|
I |
DEC / 13 |
Tiamulin or its saltsPDL |
For veterinary use, including but not limited to: Tiamulin fumarate
|
I |
DEC / 18 |
Tiaprofenic acid or its saltsPDL |
|
I |
DEC / 13 |
Ticagrelor or its derivativesPDL |
|
I |
DEC / 13 |
Ticarcillin or its salts or derivativesPDL |
For veterinary use
|
I |
DEC / 13 |
Ticlopidine or its saltsPDL |
|
I |
DEC / 13 |
TigecyclinePDL |
|
I |
DEC / 13 |
TildrakizumabPDL |
|
I |
JUL / 21 |
Tilidine and its salts, derivatives and salts of derivativesN |
|
I |
JUN / 02 |
Tiludronic acid or its saltsPDL |
|
I |
DEC / 13 |
Timolol or its saltsPDL |
|
I |
DEC / 13 |
TinidazolePDL |
|
I |
DEC / 13 |
Tinzaparin or its saltsPDL |
|
I |
DEC / 13 |
Tioconazole and its salts.. |
in preparations for intra-vaginal use |
III |
OCT / 98 |
Tioconazole and its salts... |
in preparations for topical use |
U |
OCT / 98 |
Tioconazole or its saltsPDL |
For human use, except in preparations for topical or vaginal use
|
I |
DEC / 13 |
Tiotropium bromidePDL |
|
I |
DEC / 13 |
Tipiracil or its saltsPDL |
|
I |
MAR / 18 |
Tipranavir or its saltsPDL |
|
I |
DEC / 13 |
Tirofiban or its salts or derivativesPDL |
|
I |
DEC / 13 |
TisagenlecleucelPDL |
|
I |
OCT / 18 |
TixagevimabPDL |
|
I |
JUN / 22 |
Tizanidine or its saltsPDL |
|
I |
DEC / 13 |
Tobramycin or its salts or derivativesPDL |
|
I |
DEC / 13 |
Tocainide or its saltsPDL |
|
I |
DEC / 13 |
Toceranib or its saltsPDL |
|
I |
DEC / 13 |
TocilizumabPDL |
|
I |
DEC / 13 |
Tofacitinib or its saltsPDL |
|
I |
APR / 14 |
TolazamidePDL |
|
I |
DEC / 13 |
Tolazoline or its saltsPDL |
|
I |
DEC / 13 |
TolbutamidePDL |
|
I |
DEC / 13 |
TolcaponePDL |
|
I |
DEC / 13 |
Tolfenamic acid or its salts or derivativesPDL |
|
I |
DEC / 13 |
Tolmetin or its saltsPDL |
|
I |
DEC / 13 |
Tolterodine or its saltsPDL |
|
I |
DEC / 13 |
Toltrazuril or its salts or derivativesPDL |
Including but not limited to Ponazuril
|
I |
DEC / 13 |
Tolvaptan or its derivativesPDL |
|
I |
DEC / 13 |
TopiramatePDL |
|
I |
DEC / 13 |
Topotecan or its saltsPDL |
|
I |
DEC / 13 |
Torasemide or its saltsPDL |
|
I |
DEC / 13 |
Toremifene or its saltsPDL |
|
I |
DEC / 13 |
Trabectedin or its salts or derivativesPDL |
|
I |
DEC / 13 |
TralokinumabPDL |
|
I |
NOV / 21 |
Tramadol, its salts, isomers and salts of isomers and the following derivatives of tramadol and the salts, isomers and salts of isomers of those derivatives: O-desmethyltramadol; N,O-didesmethyltramadolN |
|
I |
MAR / 22 |
Trametinib or its salts or derivativesPDL |
Including but not limited to Trametinib dimethylsulfoxide.
|
I |
DEC / 13 |
Trandolapril or its salts or derivativesPDL |
|
I |
DEC / 13 |
Tranexamic acidPDL |
|
I |
DEC / 13 |
TranylcyprominePDL |
|
I |
DEC / 13 |
TrastuzumabPDL |
|
I |
DEC / 13 |
Trastuzumab deruxtecanPDL |
|
I |
JUL / 21 |
Trastuzumab emtansinePDL |
|
I |
DEC / 13 |
Trazodone or its saltsPDL |
|
I |
DEC / 13 |
TreosulfanPDL |
|
I |
DEC / 13 |
TretaminePDL |
|
I |
DEC / 13 |
Tretinoin or its salts or derivativesPDL |
|
I |
DEC / 13 |
Triamcinolone acetonide |
in an aqueous nasal spray that delivers 55 mcg per metered spray for adults and children 12 years of age and older, in package sizes containing more than 120 metered sprays
|
II |
JAN / 15 |
Triamcinolone acetonide. |
in an aqueous nasal spray that delivers 55 mcg per metered spray for adults and children 12 years of age and older, in package sizes containing no more than 120 metered sprays
|
III |
JAN / 15 |
Triamterene or its saltsPDL |
|
I |
DEC / 13 |
Tricaine or its saltsPDL |
|
I |
DEC / 13 |
Trientine or its saltsPDL |
|
I |
DEC / 20 |
Triethanolamine oleate |
|
III |
SEP / 98 |
Triethanolamine salicylate |
in concentrations greater than 20% |
III |
SEP / 98 |
Triethanolamine salicylate. |
in concentrations up to and including 20% |
U |
|
Trifarotene or its saltsPDL |
|
I |
FEB / 20 |
Trifluoperazine or its saltsPDL |
|
I |
DEC / 13 |
Triflupromazine or its saltsPDL |
|
I |
DEC / 13 |
TrifluridinePDL |
|
I |
DEC / 13 |
TriheptanoinPDL |
except in preparations for topical use
|
I |
MAY / 21 |
Trihexyphenidyl or its saltsPDL |
|
I |
DEC / 13 |
Triiodothyropropionic acidPDL |
|
I |
DEC / 13 |
TrilostanePDL |
|
I |
DEC / 13 |
Trimebutine or its saltsPDL |
|
I |
DEC / 13 |
Trimeprazine or its saltsPDL |
For human use.
|
I |
DEC / 13 |
TrimethadionePDL |
|
I |
DEC / 13 |
Trimethaphan camsylatePDL |
|
I |
DEC / 13 |
Trimethoprim or its saltsPDL |
|
I |
DEC / 13 |
Trimetrexate or its saltsPDL |
|
I |
DEC / 13 |
Trimipramine or its saltsPDL |
|
I |
DEC / 13 |
TrioxsalenPDL |
|
I |
DEC / 13 |
Tripelennamine and its salts |
|
III |
SEP / 98 |
Triprolidine |
|
III |
SEP / 98 |
Triptorelin or its salts or derivativesPDL |
|
I |
DEC / 13 |
TroglitazonePDL |
|
I |
DEC / 13 |
Tropicamide or its saltsPDL |
For human use - in preparations for parenteral or ophthalmic use, except when sold for use in diagnostic procedures to an optometrist registered in a province of Canada.
|
I |
DEC / 13 |
Tropicamide or its saltsPDL |
For veterinary use.
|
I |
DEC / 13 |
Trospium chloridePDL |
|
I |
DEC / 13 |
Trovafloxacin or its salts or derivativesPDL |
including but not limited to alatrofloxacin
|
I |
DEC / 13 |
Tubocurarine chloridePDL |
|
I |
DEC / 13 |
Tucatinib or its salts or derivativesPDL |
|
I |
JUL / 20 |
TulathromycinPDL |
For veterinary use.
|
I |
DEC / 13 |
TybamatePDL |
|
I |
DEC / 13 |
Tylosin or its salts or derivativesPDL |
Including but not limited to: Tildipirosin, tilmicosin, tylvalosin.
|
I |
DEC / 18 |
Typhoid vaccines/Salmonella Typhi vaccines |
|
I |
FEB / 02 |
Tyrothricine |
|
III |
SEP / 98 |
Ulipristal or its salts or derivativesPDL |
Including but not limited to Ulipristal acetate.
|
I |
DEC / 13 |
Umeclidinium or its salts or derivativesPDL |
|
I |
FEB / 14 |
Upadacitinib or its saltsPDL |
|
I |
FEB / 20 |
Uracil and its saltsPDL |
When sold for the treatment of cancer.
|
I |
DEC / 13 |
Uracil mustard or its saltsPDL |
|
I |
DEC / 13 |
Urea |
in topical preparations in concentrations of more than 25% |
II |
SEP / 98 |
UrokinasePDL |
|
I |
DEC / 13 |
Ursodeoxycholic acid or its saltsPDL |
|
I |
DEC / 13 |
UstekinumabPDL |
|
I |
DEC / 13 |
Vaccines |
(except for - those which are part of a routine immunization program in most/all provinces and territories: Diphtheria toxoid, Tetanus toxoid, Pertussis, Poliomyelitis, Haemophilus influenza type B, Measles, Mumps, Pneumococcus, Rubella, Hepatitis B Pediatric, Influenza, cholera vaccine (oral, inactivated) when used for prophylaxis against traveller's diarrhea & due to enterotoxigenic escherichia coli (ETEC); and those requiring special enhanced public access due to disease outbreaks: Meningococcus) |
I |
FEB / 02 |
Vaccines |
which are part of a routine immunization program in most/all provinces and territories: Diptheria toxoid, Tetanus toxoid, Pertussis, Poliomyelitis, Haemophilus influenza type B, Measles, Mumps, Pneumococcus, Rubella, Hepatitis B Pediatric, Influenza, cholera vaccine (oral, inactivated) when used for prophylaxis against traveller's diarrhea & due to enterotoxigenic escherichia coli (ETEC); and those requiring special enhanced public access due to disease outbreaks: Meningococcus
|
II |
FEB / 02 |
Valaciclovir or its saltsPDL |
|
I |
DEC / 13 |
Valdecoxib or its saltsPDL |
|
I |
DEC / 13 |
Valganciclovir or its salts or derivativesPDL |
|
I |
DEC / 13 |
Valproic acid or its saltsPDL |
Including but not limited to Divalproex sodium
|
I |
DEC / 13 |
Valrubicin or its derivativesPDL |
|
I |
DEC / 13 |
Valsartan or its salts or derivativesPDL |
|
I |
DEC / 13 |
Vancomycin or its salts or derivativesPDL |
Including but not limited to Telavancin.
|
I |
DEC / 13 |
Vandetanib or its salts or derivativesPDL |
|
I |
DEC / 13 |
Vardenafil or its saltsPDL |
|
I |
DEC / 13 |
Varenicline or its saltsPDL |
|
I |
DEC / 13 |
Varicella Zoster immune globulin |
|
I |
FEB / 02 |
Varicella vaccine (chicken pox) |
|
I |
FEB / 02 |
Vasopressin or its saltsPDL |
|
I |
DEC / 13 |
Vecuronium bromidePDL |
|
I |
DEC / 13 |
Vedaprofen or its salts or derivativesPDL |
|
I |
DEC / 13 |
VedolizumabPDL |
|
I |
MAR / 15 |
Vegetable tar |
except shampoos in concentrations of 5% or less |
III |
SEP / 98 |
Velaglucerase alfaPDL |
|
I |
DEC / 13 |
VelpatasvirPDL |
|
I |
AUG / 16 |
Vemurafenib or its salts or derivativesPDL |
|
I |
DEC / 13 |
Venetoclax or its saltsPDL |
|
I |
NOV / 16 |
Venlafaxine or its saltsPDL |
|
I |
DEC / 13 |
Verapamil or its saltsPDL |
|
I |
DEC / 13 |
Veratrum album or its alkaloids or their saltsPDL |
For human use.
|
I |
DEC / 13 |
Veratrum viride or its alkaloids or their saltsPDL |
For human use
|
I |
DEC / 13 |
Vernakalant or its saltsPDL |
|
I |
APR / 17 |
Verteporfin or its salts or derivatives PDL |
|
I |
DEC / 13 |
VidarabinePDL |
|
I |
DEC / 13 |
Vigabatrin or its salts or derivativesPDL |
|
I |
DEC / 13 |
Vilanterol or its saltsPDL |
Including but not limited to Vilanterol trifenatate
|
I |
DEC / 13 |
Vilazodone or its saltsPDL |
|
I |
AUG / 15 |
Vinblastine or its saltsPDL |
|
I |
DEC / 13 |
Vincristine or its saltsPDL |
|
I |
DEC / 13 |
Vindesine or its saltsPDL |
|
I |
DEC / 13 |
Vinorelbine or its saltsPDL |
|
I |
DEC / 13 |
Viomycin or its salts or derivativesPDL |
|
I |
DEC / 13 |
Virginiamycin or its salts or derivativesPDL |
|
I |
DEC / 18 |
VismodegibPDL |
|
I |
DEC / 13 |
Vitamin APDL |
For human use - in oral dosage forms containing more than 10,000 International Units of Vitamin A per dosage form or, where the largest recommended daily dosage shown on the label would, if consumed by a person, result in the daily intake by that person of more than 10,000 International Units of Vitamin A.
|
I |
DEC / 13 |
Vitamin B12 with Intrinsic Factor ConcentratePDL |
|
I |
DEC / 13 |
Vitamin DPDL |
For human use - in oral dosage form containing more than 62.5 mcg or 2,500 International Units of Vitamin D per dosage form, or where the largest recommended daily dosage shown on the label would result in the daily intake by that person of more than 62.5 mcg or 2,500 International Units of Vitamin D
|
I |
FEB / 21 |
Vitamin KPDL |
For human use - except Vitamin K1 or Vitamin K2 sold (a) for external use in humans; or (b) in an oral dosage form for use in humans if the maximum recommended daily dose is 0.120 mg or less.
|
I |
DEC / 13 |
Vitamins |
in injectable form, except those listed in Schedule I
|
II |
SEP / 98 |
Vitamins in injectable form for parenteral nutrition |
|
I |
JAN / 03 |
Vorapaxar or its saltsPDL |
|
I |
AUG / 16 |
Voretigene neparvovecPDL |
|
I |
DEC / 20 |
VoriconazolePDL |
|
I |
DEC / 13 |
VorinostatPDL |
|
I |
DEC / 13 |
Vortioxetine or its saltsPDL |
including but not limited to vortioxetine hydrobromide
|
I |
DEC / 14 |
Voxilaprevir or its saltsPDL |
|
I |
SEP / 17 |
Xanthinol nicotinatePDL |
|
I |
DEC / 13 |
Xylazine or its saltsPDL |
|
I |
DEC / 13 |
Xylometazoline and it salts |
in nasal preparations for pediatric use (0.05%) |
II |
SEP / 98 |
Xylometazoline and its salts |
in nasal preparations for adults (0.1%)
|
U |
SEP / 98 |
Yellow Fever vaccine |
|
I |
FEB / 02 |
Yohimbine or its saltsPDL |
|
I |
DEC / 13 |
Zafirlukast or its saltsPDL |
|
I |
DEC / 13 |
Zalcitabine or its saltsPDL |
|
I |
DEC / 13 |
Zaleplon or its salts or its derivativesPDL |
|
I |
NOV / 18 |
Zanamivir or its salts or derivativesPDL |
|
I |
DEC / 13 |
Zanubrutinib or its saltsPDL |
|
I |
MAY / 21 |
ZeranolC |
|
I |
SEP / 98 |
ZidovudinePDL |
|
I |
DEC / 13 |
Zinc chloride in injectable form for parenteral nutrition |
|
I |
JAN / 03 |
Zinc sulfate in injectable form for parenteral nutrition |
|
I |
JAN / 03 |
Zipeprol and any salt thereofC |
|
I |
NOV / 20 |
Ziprasidone or its saltsPDL |
|
I |
DEC / 13 |
Zoledronic acid or its salts or derivativesPDL |
|
I |
DEC / 13 |
Zolmitriptan or its saltsPDL |
|
I |
DEC / 13 |
Zolpidem and any salt thereofTS |
|
I |
JAN / 03 |
Zomepirac or its saltsPDL |
|
I |
DEC / 13 |
Zopiclone or its saltsPDL |
|
I |
DEC / 13 |
ZucapsaicinPDL |
|
I |
DEC / 13 |
Zuclopenthixol or its salts or derivativesPDL |
Including but not limited to zuclopenthixol decanoate, zuclopenthixol hydrochloride.
|
I |
DEC / 13 |